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ABSTRACT OF THE DISSERTATION
AN INTEGRATED NEUROIMAGING APPROACH FOR THE PREDICTION AND
ANALYSIS OF ALZHEIMER’S DISEASE AND ITS PRODROMAL STAGES
by
Qi Zhou
Florida International University, 2015
Miami, Florida
Professor Malek Adjouadi, Major Professor
This dissertation proposes to combine magnetic resonance imaging (MRI), positron
emission tomography (PET) and a neuropsychological test, Mini-Mental State
Examination (MMSE), as input to a multidimensional space for the classification of
Alzheimer’s disease (AD) and it’s prodromal stages including amnestic MCI (aMCI) and
non-amnestic MCI (naMCI). An assessment is provided on the effect of different MRI
normalization techniques on the prediction of AD. Statistically significant variables
selected for each combination model were used to construct the classification space using
support vector machines. To combine MRI and PET, orthogonal partial least squares to
latent structures is used as a multivariate analysis to discriminate between AD, early and
late MCI (EMCI and LMCI) from cognitively normal (CN)s. In addition, this dissertation
proposes a new effective mean indicator (EMI) method for distinguishing stages of AD
from CN. EMI utilizes the mean of specific top-ranked measures, determined by
incremental error analysis, to achieve optimal separation of AD and CN.

vii

For AD vs. CN, the two most discriminative volumetric variables (right hippocampus and
left inferior lateral ventricle), when combined with MMSE scores, provided an average
accuracy of 92.4% (sensitivity: 84.0%; specificity: 96.1%). MMSE scores were found to
improve classification accuracy by 8.2% and 12% for aMCI vs. CN and naMCI vs. CN,
respectively. Brain atrophy was almost evenly seen on both sides of the brain for AD
subjects, which was different from right side dominance for aMCI and left side
dominance for naMCI. Findings suggest that subcortical volume need not be normalized,
whereas cortical thickness should be normalized either by intracranial volume or the
mean thickness. Furthermore, MRI and PET had comparable predictive power in
separating AD from CN. For the EMCI prediction, cortical thickness was found to be the
best predictor, even better than using all features together. Validation with an external
test set demonstrated that best of feature-selected models for the LMCI group was able to
classify 83% of the LMCI subjects. The EMI-based method achieved an accuracy of 92.7%
using only MRI features. The performance of the EMI-based method along with its
simplicity suggests great potential for its use in clinical trials.
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CHAPTER 1
1. INTRODUCTION

1.1

Alzheimer’s Disease

Nowadays more and more old people are suffering from Alzheimer’s disease (AD) as a
result of prolonged life expectancy (Duchesne, et al., 2008). AD is a progressively
neurodegenerative disease, and is the most common form of dementia, accounting for 60%
to 70% of the dementia cases(Organization, 2012). It is a syndrome that affects memory,
thinking orientation, language, judgment, comprehension and so on. Estimates from the
Alzheimer Association (alz.org) as of March 2012 indicate that 5.4 million Americans are
diagnosed with AD, and over 95% of this population are 65 years of age or older. This
estimate of AD population is expected to reach 16 million by 2050, a disturbing prospect.
Also, nearly half of the population over 85 years of age is affected by AD (Organization,
2012).

AD patients display disease-related regional cerebral atrophy, which can be distinguished
from normal aging (Fox and Schott, 2004; Ridha, et al., 2006). In AD, atrophy is often
observed in regions which are closely related to neurodegeneration. Various studies have
shown that atrophy in regions like the hippocampus (Apostolova, et al., 2012; Laakso, et
al., 1995b; Leclerc and Abulrob, 2013; Scahill, et al., 2002), amygdala (Cuenod, et al.,
1993; Laakso, et al., 1995b) and ventricles (Nestor, et al., 2008c; Thompson, et al., 2004b)
is correlated to AD. Moreover, determination of the key atrophied regions across the entire
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brain could be used as parameters for the delineation of AD patients from cognitively
normal subjects (CN).

Transitional stage of AD is commonly referred as mild cognitive impairment (MCI),
which is intermediate between cognitive normal (CN) controls and patients with AD. It is
subdivided as early and late MCI (EMCI and LMCI) in the late two phases of
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (ADNI GO and ADNI 2).
EMCI is characterized as very mild memory impairment that is intermediate between CN
and LMCI (Herholz, et al., 2002; Landau, et al., 2012). Such division of MCI is preferred
from the traditional classification of MCI as a general group as it makes differential
diagnosis of AD more specific. It is expected that prediction of EMCI will be more
challenging than for LMCI, while evidently it will be more beneficial to the patients if a
correct diagnosis is made at the EMCI stage.

MCI were also divided into amnestic MCI (aMCI) and non-amnestic MCI (naMCI) and
were studied separately as early findings suggest that these two different types of MCI
have their own distinctive features that could delineate them (Ellison, et al., 2008; NutterUpham, et al., 2008). More specifically, this could help in predicting the conversion of
MCI as has been reported by Ferman et al. that naMCIs were more likely to develop
dementia with Lewy body (DLB) while patients with aMCI are more likely to convert to
AD (Ferman, et al., 2013).
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Mini-Mental State Examination (MMSE) is a neuropsychological test that is most often
administered to screen patients for cognitive impairment and dementia (Folstein, et al.,
1975). MMSE is used to judge the severity of cognitive impairment by administrating 30
questions aimed at testing the subject’s orientation to time and place, attention and
calculation capabilities, as well as response to recall, language and complex commands.
The frequent use of MMSE in clinical environments makes it interesting to investigate its
discriminative power in classifying AD subjects as compared to MRI-based measures.

1.2

Biomarkers of Alzheimer’s Disease

There are multiple biomarkers that have been shown effective in the diagnosis of AD and
MCI. Magnetic resonance imaging (MRI) is commonly used for analyzing regional
volumetric atrophy (Fennema‐Notestine, et al., 2009; Fox, et al., 1999; Jack, et al., 1997;
Wang, et al., 2011), cortical thinning (Dickerson, et al., 2009a; Eskildsen, et al., 2013),
shape of specific regions (Achterberg, et al., 2014; Csernansky, et al., 2005; Wang, et al.,
2007b) and structural/functional connectivity (Gour, et al., 2013; Haase, et al., 2013;
Wang, et al., 2007a). In addition, extracellular beta-amyloid (A ) deposition (Hardy and
Allsop, 1991b) and tau protein abnormalities (Mudher and Lovestone, 2002a) were
reported as being the fundamental causes of the disease, making biomarkers capable of
characterizing these critical features essential in the diagnosis of AD. Among these,
Positron emission tomography (PET) imaging modality has been shown to be an efficient
biomarker for evaluating amyloid plaque level and hypometabolism of the brain, which
contain discriminative information for AD staging (Herholz, et al., 2002; Mosconi, et al.,

3

2008; Nordberg, et al., 2010a; Nordberg, et al., 2010b). Another biomarker is singlephoton emission computerized tomography (SPECT), which measures regional cerebral
perfusion (Hirao, et al., 2005; Jagust, et al., 2001; Johnson, et al., 1998).

Others include Cerebrospinal fluid (CSF) biomarker by analyzing level of β amyloid
(Aβ42) and total tau protein (T-tau) of CSF (Blennow and Hampel, 2003; Hansson, et
al., 2006; Mattsson, et al., 2009), EEG biomarker for estimating the power spectrum
(Besthorn, et al., 1994; Locatelli, et al., 1998) and Apolipoprotein E (APOE) genotype
indicating higher risk for AD with the presence of the ε4 allele (Bickeböller, et al., 1997;
Ganzer, et al., 2003). These biomarkers have been widely used to guide clinicians for
planning a course of action.

More recently, some studies have combined two or more of these biomarkers to explore
their complementary information for improved discriminative power (Fan, et al., 2008b;
Walhovd, et al., 2010a; Westman, et al., 2012a; Zhang, et al., 2011). For example, Zhang
et al. combined biomarkers of MRI, PET and CSF using a proposed multimodal data
fusion technique (Zhang, et al., 2011), and Westman et al. combined MRI and CSF using
orthogonal partial least squares to latent structures (OPLS) analysis method (Westman, et
al., 2012a). Specifically, some studies combined neuropsychological tests with medical
imaging modalities. The cost-benefit of combining multiple biomarkers is of great
concern as the use of multiple biomarkers often result in unaffordable costs (Westman, et
al., 2012a).
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1.3

Research Purpose and Significance

This dissertation investigates the classification of AD, aMCI and naMCI by combining
subcortical volumes of MRI with a neuropsychological test (Mini-Mental State
Examination (MMSE)), which is most often administered to screen patients for cognitive
impairment and dementia. This study demonstrates the merits of MMSE and extends its
use to the discrimination of different stages of AD when used in conjunction with select
volumetric variables. To the best of our knowledge, this study is the first that investigates
the impact of combining MRI at baseline with MMSE for the detection of AD, aMCI and
naMCI using support vector machine (SVM) methodology. However, since MMSE as a
cognitive score in combination with other biomarkers can introduce an unfair bias in the
analysis, the work in this dissertation reflects the results under the two conditions which
are with and without inclusion of MMSE. Another important contribution of this study is
the development of a fully automated feature extraction technique, which in its initial step
associates equal weights to each of the measured volumes, and yet as its outcome is a
ranking of the volumes that can be used as variables in a multidimensional decisional
space for optimal classification (Chapter 2).

In this dissertation, single-measure models and hierarchical models with and without
normalization are both examined to find the optimal model. Single measure models
include one of the regional MRI measures (subcortical volume, cortical thickness and
surface area) or the neuropsychological test, Mini-Mental State Examination (MMSE). A
hierarchical model combines two or more of the single-measure models to examine if the
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interaction augments the classification process. The specific aims of this study are thus to
determine: (1) the impact of neuropsychological test (MMSE) towards the classification;
(2) the combination of regional measures and MMSE that yields the best classification
performance; and (3) which normalization scheme should be employed to achieve a
better classification performance (Chapter 3).

To combine MRI and PET, we included all applicable FreeSurfer segmentation and
parcellation of MRI scans (i.e. subcortical volumes, cortical volumes, cortical thickness,
surface areas and hippocampus subfields) to explore full patterns of atrophy reflected by
MRI since, as it has been reported, volumetric measures of a few pre-defined structures
cannot capture the spatio-temporal pattern of structural abnormalities in their entirety
(Fan, et al., 2008b). We also included extracted features from AV-45 PET and FDG PET
to investigate complimentary predictive information of MRI and the two PET imaging
modalities using OPLS. All features were inputted to OPLS for a multivariate analysis of
EMCI, LMCI and AD against cognitively normal controls (CN). The aims were: 1) To
explore the individual and combined discriminative power of MRI and PET features in
separating EMCI, LMCI and AD from CN and determine the best predictive models of
EMCI, LMCI and AD; 2) to find out if feature selection techniques enhance prediction;
and 3) to investigate efficiency of the models by validating with an external dataset and
explore how best AD models would predict EMCI and LCMI subjects (Chapter 4).

Also a completely new approach without projection is proposed using effective mean
indicator (EMI). EMI is a value associated with each subject and generated by averaging
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a specific number of the top statistically significant MRI measures divided by the
corresponding mean of each measure among CN subjects. Prediction is just as simple as
comparing the EMI of the testing subjects with the threshold found by the training
process (Chapter 5).

1.4

Literature Survey

Recently, some studies have combined two or more of these biomarkers to explore their
complementary information for improved discriminative power (Fan, et al., 2008b;
Walhovd, et al., 2010a; Westman, et al., 2012a; Zhang, et al., 2011). For example, Zhang
et al. combined biomarkers of MRI, PET and CSF using a proposed multimodal data
fusion technique (Zhang, et al., 2011), Westman et al. combined MRI and CSF using
orthogonal partial least squares to latent structures (OPLS) analysis method (Westman, et
al., 2012a) and Walhovd et al. and Daoqiang et al. reported that combination of MRI,
PET and CSF biomarkers yields the most suitable and complementary indicators for the
diagnosis of AD (or MCI) (Walhovd, et al., 2010c; Zhang, et al., 2011). The cost-benefit
of combining multiple biomarkers is of great concern as the use of multiple biomarkers
often result in unaffordable costs (Westman, et al., 2012a).

Important tasks to be considered in AD classification studies include the choice of
parameters, the way these parameters ought to be combined, and in determining the preprocessing techniques to be employed in order to enhance the prospects of classification.
Two essential questions that need to be addressed for AD classification studies are: (1)
which regional MRI measures produced by Freesurfer are statistically significant for
7

classification of AD subjects?; and (2) which normalization approach should be
employed to minimize bias due to differences in head size and brain structure in order to
enhance the classification performance?

Westman and his colleagues have investigated some aspects of the aforementioned issues
using a supervised multivariate data analysis using the orthogonal projections to latent
structures (OPLS) model (Westman, et al., 2013). OPLS is similar to principal
component analysis (PCA) as they both are linear decomposition techniques and project
the original data to the found latent variables. The approach of this study is an extension
of a previous study (Qin, et al., 2013), which proposes to construct for each classification
model an optimal decisional space using the most statistically significant variables. The
number of dimensions in the classifier is determined by an incremental error analysis,
which in turn defines and ranks variables on their statistical significance to be used as
input to an SVM-based classification process.
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CHAPTER 2

2. CONSTRUCTING AN OPTIMAL DECISIONAL SPACE

2.1

Background

In literature, researchers have combined neuropsychological tests with medical imaging
modalities. Among them, Ewers et al. combined the primary MRI and CSF biomarkers
with neuropsychological tests to predict conversion from MCI to AD (Ewers, et al.,
2012). With a population of 81 AD patients and 101 elderly control subjects, they
determined that single-predictor models yielded comparable accuracies as multi-predictor
models, with a prediction accuracy ranging from the mid-60s to a high of 68.5% when
the entorhinal cortex is used as the single predictor. Gomar et al. investigated in a 2-year
longitudinal study the usefulness of combining different variables drawn from a series of
biomarkers with the inclusion of cognitive markers and other risk factors to likewise
predict conversion from MCI to AD (Gomar, et al., 2011). Their study involved the use
of brain volumes, CFS, along with other cognitive markers. Their findings suggest that
cognitive markers at baseline are better suited as predictors for the conversion than the
temporal neurobiological markers. Furthermore, they also suggest that sharp decline in
functional ability is a better predictor for the conversion than the biomarkers. These
findings add credence to the results obtained in this study, in that with the inclusion of
neuropsychological data, accuracy in delineating AD from controls is shown to increase
to over 90%. It is noted that in both of these studies, which focus more on the conversion
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from MCI to AD, the volumetric measures of the different brain regions were selected
manually, and both studies relied on the ADNI (Alzheimer's Disease Neuroimaging
Initiative) public database. As such, the proposed study which provides an automated
approach at ranking the neurobiological variables will augment and complement such
findings, as reported in both of these studies, to reflect more globally patterns of
structural and physiological abnormalities in their entirety (Fan, et al., 2008a), and with
statistical context for a more meaningful choice of the different variables.

2.2

Methodology

The general structure of the proposed approach is presented in Figure 1, showing the
main steps of the whole process from acquisition of the MRI scans, through the sorting
and selection of variables or features that will constitute the decisional space for the
classification process using the well-established SVM classifier. The proposed approach
is also open to the use of other alternative classification algorithms such as artificial
neural networks, optimal discriminant analysis, and so on. This study opted for SVM
only for its implementation simplicity.

2.2.1

Subjects

A total of 309 participants were recruited from Wien Center for Alzheimer’s Disease and
Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL as shown in Table 1
between 2005 and 2008. All participants have taken the Folstein Mini-Mental State
Examination (Folstein, 1990) with a minimum score of 15. The study was approved by
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the Mount Sinai Medical Center Institutional Review Board with informed consent
provided by the subjects or legal representatives. All subjects had: (1) a neurological and
medical evaluation by a physician; (2) Mini-Mental State Examination (MMSE) (3) a
structural volumetrically acquired MRI scan of the brain. MMSE was used as the index
of cognitive ability and sum of boxes from the Clinical Dementia Rating Scale (CDR-sb)
was used clinically as the index of functional ability.

Figure 1: General structure of the classification approach
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Table 1: Participant demographics and characteristics in this study
Characteristic
Age
Gender(F/M)

CN (n = 127)

naMCI (n = 56)

aMCI (n = 67)

AD (n = 59)

p-value*

72.6 ± 6.0

74.1 ± 6.5

75.2 ± 6.8

79.8 ± 6.5

< 0.001

91 / 36

36 / 20

36 / 31

33 / 26

ns†

14.4 ± 3.6

11.75 ± 3.6

13.3 ± 3.7

13.1 ± 3.9

0.035

28.7 ± 1.4

26.9 ± 2.3

26.6 ± 2.5

22.7 ± 3.3

< 0.001

Education
(years)
MMSE

Unless otherwise noted, data are presented as mean ± S.D. *P-value based on Student’s t-test
between CN and AD unless otherwise specified and those less than significance level 0.05 are
bolded. †A Fisher’s exact test was performed between AD and CN, and p value shows that
gender effect is not significant at significance level of 0.05.

The cognitive diagnosis was made using a combination of the physician’s diagnosis and
the neuropsychological diagnosis, as described previously (Loewenstein, et al., 2000).
The etiological diagnosis was made by the examining physician. The diagnosis of
cognitive normal (CN) required that the physician’s diagnosis was CN and no cognitive
test scores were ≥1.5 SD below age and education-corrected means. A probable AD
diagnosis required a dementia syndrome and the National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders
Association criteria for AD (McKhann, et al., 1984). The diagnosis of aMCI was
rendered by 1) a clinical impression by the examining physician of a history of MCI but
no significant functional impairment and did not meet Diagnostic and Statistical Manual
of Mental Disorder-4th edition (DSM-IV) criteria (Association and DSM-IV., 1994) for
dementia. This diagnosis was confirmed by a neuropsychological evaluation in which one
or more tests of memory had to fall 1.5 SD or more below expected normative values.
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The diagnosis of naMCI was rendered by 1) a clinical impression by the examining
physician of a history of MCI but no significant functional impairment and did not meet
DSM-IV criteria for dementia. This diagnosis was confirmed by a neuropsychological
evaluation in which one or more tests of non-memory function (e.g., Trails B,
Similarities, and Category Fluency) had to fall 1.5 SD or more below expected normative
values but all tests of memory scored within normal limits.

2.2.2

MRI Protocol and Analysis

MRI scans were acquired on a 1.5-T machine (Siemen's Symphony, Iselin, N.J., USA, or
General Electric, HDX, Milwaukee, Wisc., USA) using a proprietary 3D-magnetizationprepared rapid-acquisition gradient echo (3D MPRAGE) or 3D spoiled gradient echo
sequences (FSPGR). Specifications for 3D MPRAGE include coronal sections with a 1.5
mm gap in thickness; section interval, 0.75 mm; TR, 2190 ms; TE, 4.38 ms; TI, 1100 ms;
FA, 15°; NEX, 1; matrix, 256 × 256; FOV, 260 mm; bandwidth, 130 Hz/pixel;
acquisition time, 9 minutes; phase-encoding direction, right to left. Specifications for 3D
FSPGR were the following: 140 contiguous coronal sections of 1.2 mm thickness;
contiguous images with no section interval; TR, 7.8 ms; TE, 3.0 ms; inversion recovery
preparation time, 450 ms; flip angle, 12°; NEX, 1; matrix, 256 × 256; FOV, 240 mm;
bandwidth, 31.25 Hz/pixel; acquisition time, 6–7 minutes; phase-encoding direction,
right to left.
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FreeSurfer pipeline (version 5.1.0) was applied to the MRI scans to produce 55
volumetric variables, including 45 subcortical regions (e.g. left lateral ventricle, corpus
callosum anterior, right hippocampus, etc.) and 10 morphometric statistics (e.g. left
hemisphere gray matter volume, total cortical volume, etc.). Out of the 45 volumetric
variables, 4 of them, namely left white-matter-hypointensities (WMH), right WMH, left
non-WMH, and right non-WMH were excluded since they were all characterized by zero
values. Therefore, each MRI scan includes 41 regional and 10 morphometric volumes. It
was determined that MRI scans from the two scanner machines did not change the
variance of volume difference when comparing subcortical volumes (FreeSurfer
segmentation) from the test-retest scans acquired in a fixed machine (Han, et al., 2006;
Jovicich, et al., 2009), thus no correction is needed for scanner difference.

2.2.3

Feature Extraction and Variable Selection

AD patients suffer from cerebral atrophy, which can be distinguished from normal aging
(Fox and Schott, 2004), and specific regions are more atrophied along the progression of
AD. For example, studies have shown that hippocampal atrophy is more significant as
disease progresses (Scahill, et al., 2002). Determination of the key atrophied/enlarged
regions of interest (ROIs) that define the pattern of atrophy may help delineate AD and
MCI from normal controls. To this end, a rigorous blind feature selection technique is
proposed, where no prior assumptions of ROIs are assumed and with equal weights
assigned to each of the volumetric measures so as to eliminate any bias. The outcome of
this selection process is the determination of those statistically significant features that
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form an optimal decisional space bound to yield accurate classification results of AD,
MCI (aMCI, naMCI) and controls.

Freesurfer is a popular highly automated MRI image processing software widely used to
generate regional measures from MRI scans. The advantages of Freesurfer over
traditional manual segmentations and measures are its high automation and independence
from operator subjectivity. Freesurfer is also accurate, precise and has been tested on
large cohorts of studies in AD classification research (Cuingnet, et al., 2011; Ewers, et
al., 2012; Qin, et al., 2013; Westman, et al., 2013).

Freesurfer pipeline version 5.1.0, widely used in AD research (Cuingnet, et al., 2011;
Ewers, et al., 2012; Qin, et al., 2013; Westman, et al., 2013; Zhang, et al., 2011), was
applied to all the MRI scans to produce 55 volumetric variables, including 45 volumetric
measures of subcortical parcellation and 10 morphometric statistics. For cortical
thickness, 34 regional variables were determined for each hemisphere, resulting in 68
variables for cortical thickness measures. Also, surface area was estimated from 35
regions of the brain for each hemisphere resulting in 70 measures for the entire brain.

All volumetric variables, but for intracranial (ICV), were adjusted for ICV, age and
education as per Equation (2.1), as they were found to be significant factors as
demonstrated in Table 1.

V = V

−G

∙ (V

−V

)−G
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∙ (E − E ) − G

∙ (A − A )

(2.1)

where V is the adjusted volume, V is the unadjusted volume, V

, E and A are the

subject ICV, years of education and age (years), respectively; V

, E and A are the

corresponding means for all the control subjects. The gradients G
G

,G

and

were derived by a region specific regression against subject ICV, years of education

and age of all the participants so that the regression is fully blinded to the classifications.
As per Chiang et al.(Chiang, et al., 2011), the above regression also has the advantage
that the regressing order of the 3 factors doesn’t affect the results.

The adjusted volumes and ICV of the 51 volumetric variables are then combined with the
MMSE score to generate a 52-variable vector discriminator for each subject. A Student’s
t-test is carried out on each of the 52 variables between AD (or MCI) and CN to
determine the significance of each variable in the classification outcome and only those
with a p-value lower than significance level (α) of 0.05 are selected and ranked.

It should also be noted that, even though atrophy is what is generally sought, statistical
testing in this study considers both cases of atrophy and enlargement of brain regions,
since volumetric enlargement (i.e. ventricles filled with cerebrospinal fluid) is also shown
to be an important predictor of AD (Thompson, et al., 2004b).

Rank of the statistically significant variables provides an overall view of the
discriminative power of each variable for each classification type. Selection of these
optimal variables can be viewed as a dimensionality reduction problem, which is
performed using an incremental error analysis. The result of this analysis is the
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determination of how many of these top-ranked variables ought to be included in the
classifier to yield the best classification performance. The proposed error analysis, which
begins with the initial phase of using only the first top-ranked variable, is employed
whereby an additional next-ranked variable is introduced in the SVM classifier at each
subsequent phase and the corresponding classifier statistics (accuracy, sensitivity,
specificity) are recorded each time.

2.2.4

SVM based Classification Experiments

SVM classifier is shown to be an effective classification tool of AD and MCI (Chaves, et
al., 2009b; Kloppel, et al., 2008; Lopez, et al., 2009).The SVM as implemented in this
study uses a sequential minimal optimization (SMO) scheme to implement a L1 softmargin SVM classifier. SVM maps the original features via a kernel function to
constructs a maximum margin classifier in a high dimensional feature space. The kernel
function used in this study is the Gaussian Radial Basis Function kernel (rbf) with an
empirical scaling factor of 3.

In this study, all experiments were based on 2-fold cross validation, meaning half of the
subjects data are used as training set and the other half as testing set. The training and
testing sets were randomly assigned while the number of subjects with AD (or MCI) and
CN in each set remain fixed. To limit the potential data partitioning error introduced by
random data assignment and cross validation, the same experiment with random data
assignment was run 50 times and the average performance was recorded.
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2.3

2.3.1

Results

Rank of Variables

Based on the methodology described in section II (D), a Student’s t-test was performed
for AD vs.CN, aMCI vs. CN and naMCI vs. CN using the ICV-, education- and ageadjusted 52-variable vector discriminator. The variables found at significance level of
0.05 for MCI vs. CN and AD vs. CN were ranked and are given in Table 2 and Table 3,
respectively, which show the importance of each variable in potentially discriminating
different stages of AD. The anatomical distribution of these ROIs is shown in Figure 2.

Table 2: Significant variables for naMCI vs. CN and aMCI vs. CN

naMCI

aMCI

Rank

Variables

p-value

1

MMSE

< 0.001

2

Right-Accumbens-area

0.013

3

Right Inferior Lateral Ventricle

0.039

1

MMSE

< 0.001

2

Right-Hippocampus

< 0.001

3

Left-Hippocampus

< 0.001

4

Left-Amygdala

0.002

5

Left Inferior Lateral Ventricle

0.023

From Table 2 and Table 3, it can be observed that MMSE as a cognitive measure ranks
first for all classification types. Moreover, in comparison to MCI, the AD group is shown
to have many more significant variables than the naMCI and aMCI groups, indicating
atrophy is more serious and widely spread in the AD group. Table 2 also shows that
hippocampus atrophy is dominant in aMCI subjects as both left and right hippocampus

18

regions rank as the second and third only after MMSE. This finding is consistent with the
fact that one main characteristic of aMCI subjects is memory problem, which the
hippocampus is found to be responsible for (Juottonen, et al., 1999). Whereas
hippocampus region doesn’t show as significant in naMCI group, Accumbens and
ventricle regions do instead. The distinctive symptom of aMCI and naMCI (memory) is
consistent with the regional atrophy in these preliminary results.

Table 3: Significant variables for AD vs. CN
Rank

Variables

p-value

Rank

Variables

p-value

1

MMSE

< 0.001

15

Right Lateral Ventricle

0.002

2

Right Hippocampus

< 0.001

16

Left Lateral Ventricle

0.002

3

Left Inferior Lateral
Ventricle

< 0.001

17

Right Thalamus Proper

0.004

4

Left Amygdala

< 0.001

18

Right Ventral Diencephalon

0.007

5

Left Hippocampus

< 0.001

19

Left Thalamus Proper

0.007

< 0.001

20

Left Putamen

0.007

< 0.001

21

Corpus Callosum Central

0.010

6
7

Right Inferior Lateral
Ventricle
Right Hemisphere Cortex
Volume

8

Total Gray Volume

< 0.001

22

Right Accumbens Area

0.010

9

Right Amygdala

< 0.001

23

Corpus Callosum Posterior

0.011

10

Cortex Volume

< 0.001

24

Corpus Callosum Middle
Anterior

0.020

11

Left Hemisphere Cortex
Volume

< 0.001

25

Left Pallidum

0.026

12

Left choroid plexus

< 0.001

26

Corpus Callosum Anterior

0.028

13

Right choroid plexus

< 0.001

27

Subcortical Gray Volume

0.032

14

3rd Ventricle

< 0.001

28

Corpus Callosum Middle
Posterior

0.046
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Anatomical visualization of all the significant ROIs (excluding morphometric variables)
as shown in Figure 2 provides a general view of how the ROIs are distributed within the
brain. The figure shows that atrophy for the AD group is widely seen for a number of
regions on both hemispheres, while for aMCI atrophy is more dominant on the right side
and for naMCI all significant atrophy is seen on the left side. This finding implies the
difference of atrophy in terms of its extension and hemisphere dominance at different
stages of AD.

(a)

(b)

(c)

Figure 2: Representation of all significant regions of interest (ROIs) (excluding
morphometric variables and MMSE) using different colors for (a) AD vs. CN (b) aMCI
vs. CN (c) naMCI vs. CN
A closer inspection of the results shows that the top-ranked significant volumetric
variables, e.g. hippocampus (de Leon, et al., 1989b; Du, et al., 2001; Pennanen, et al.,
2004), ventricular (Nestor, et al., 2008b; Thompson, et al., 2004b), cortical (Du, et al.,
2001; Juottonen, et al., 1999; Pennanen, et al., 2004) and amygdala (Cuenod, et al., 1993;
Nestor, et al., 2008b), are all regions that have been proven to be effective predictors of
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AD and/or MCI by other research groups. The convergence of these findings comes in
support of the merits and usability of the ranking system developed in this study.

2.3.2

Best Variable Set based on Incremental Error Analysis

The incremental error analysis aims to determine how many top-ranked variables should
be included in order to produce the best classification results. The classification of AD,
aMCI and naMCI was performed starting from the first ranked variable, and
incrementally adding the next best ranked variable until all significant variables were
considered. The accuracy with error bars depicting the standard deviation of the 50
repetition runs is plotted in Figure 3, with the horizontal axis indicating at each step the
number of top-ranked variables that were considered.

The classification accuracy curve based on the proposed incremental error analysis,
displays a trend on how accuracy changes as more variables (one at a time) are included.
For AD vs. CN, as shown in Figure 3a, the increasing trend of the curve stops when the
first 3 variables (MMSE score, right hippocampus and left inferior lateral ventricle) are
included, yielding a peak accuracy of 92.4%. As can be seen in Figure 3b, the accuracy
peaks for the classification of naMCI when the top 2 ranked variables (MMSE and right
hippocampus) are included with a peak accuracy of 74.9%; as for aMCI, the upward
trend in accuracy is sustained up to the 3 significant variables (MMSE, right Accumbens
area and right inferior lateral ventricle) reaching a peak accuracy of 74.1%.
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The features that make up the optimal decisional space and hence produce the best
classification results are summarized in Table 4, with and without the inclusion of the
MMSE score. It can be observed that with MMSE, the performance improved
significantly for all classification types with an accuracy increment of 14.2% for AD vs.
CN, 8.2% for aMCI vs. CN and 12.0% for naMCI vs. CN. Such outcomes support the
fact that the cognitive measure as determined from MMSE test is rather important in this
type of classification. This difference in the accuracy could not otherwise be overcome
with the inclusion of additional MRI-based volumetric measures.

To have an anatomical view of these optimal decisional spaces, the brain regions
associated with the top-ranked volumetric features for each classification pair are plotted
in Figure 4, which suggests that different brain regions could be linked to the different
stages of AD.
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Figure 3: Incremental error analysis performance of accuracy with standard deviation
(S.D.) indicated as error bar (a) AD vs. CN (b) naMCI vs. CN and aMCI vs. CN with
only one side S.D. shown to avoid overlapping. (For naMCI vs. CN, though only 3
variables were shown as significant, the 4th ranked variable was included to check if the
accuracy continues to increase.)
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Best
Decisional
Spaces

Specificity

Sensitivity

Accuracy

Classification
Type
74.9
(72.2-77.6)
61.1
(53.3-68.7)
83.4
(78.7-87.4)

78.2
(73.2-80.7)
68.5
(60.9-74.4)
82.7
(75.5-86.7)

66.7
(60.8-69.5)
55.0
(49.2-62.5)
72.5
(67.0-78.0)

Without

MMSE
Right-Hippocampus

With MMSE

aMCI vs. CN

Without

MMSE
Right hippocampus
Left inferior lateral ventricle

With
MMSE
92.4
(89.8–94.6)
84.0
(77.8–88.2)
96.1
(94.5–97.6)

AD vs. CN

62.1
(52.4-69.4)
51.5
(41.1-62.5)
70.3
(55.7-80.2)

Without

MMSE
Right-Accumbens-area
Right Inferior Lateral Ventricle

74.1
(70.5-76.0)
55.2
(50.0-62.5)
82.3
(77.1-85.1)

With MMSE

naMCI vs. CN

Table 4: Summary of best performance cases based on incremental error analysis

2.3.3

Reliability of Rank and Sample Size

To evaluate the rank reliability of the variables which might be dependent on the dataset
size, a test was performed by randomly reducing the dataset to 80% and to 50% of its
original size. Then the ranks of each variable in 100 repetitions of the random experiment
were summed and averaged to get the rank expectation. The final rank was determined by
sorting the rank expectation of all variables from low to high and top 3 variables were
recorded as shown in Table 5.

(a)

(b)

(c)

Figure 4: Representation of the most significant regions that combines with MMSE
scores constitute the optimal decisional space for a) AD vs. CN b) aMCI vs. CN c)
naMCI vs. CN
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Table 5: Summary of top rank variables with varying dataset size
Dataset size

100%

80%

50%

MMSE

MMSE

MMSE

RH

RH

RH

LILV

LILV

LILV

MMSE

MMSE

MMSE

RH

RH

RH

LH

LH

LH

MMSE

MMSE

MMSE

RAA

RAA

RAA

RILV

RILV

RILV

AD vs. CN

Rank of variables

aMCI vs. CN

Rank of variables

naMCI vs. CN

Rank of variables

RH = right hippocampus, LILV = left inferior lateral ventricle, LH = left hippocampus,
RAA = right Accumbens area, RILV = right inferior lateral ventricle

2.3.4

Comparative Analysis

A comparison of classification performance with recent studies in literature is provided in
Table 6, which also shows the detailed parameters of classification experiment for better
comparison of the performance.
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27

ADNI(51/52)
ADNI(51/52)
ADNI(48/66)
ADNI(48/66)
Private(16/22)

PET
MRI + PET + CSF
MRI +PET
MRI+PET+CSF+AP
OE+Cognitive Scores
MRI

ADNI(42/38)
ADNI(42/38)
ADNI(162/137)
Private (38/24)
Private(127/59)

MRI
MRI + CSF
MRI
EEG
MRI + MMSE

MRI

MRI

(Group I) Private
(20/20)
(Group II) Private
(14/14)
(Group III) Private
(33/57)

ADNI(51/52)

CSF

MRI

ADNI(51/52)

Source of Data
(AD/CN)

MRI

Imaging Modality/
Biomarkers

50 (2 folds)

-(-)

- (2 folds)

N/A

92.4

84.0

-

88.8

82.5

81.1

Leave-one-out
N/A

92.9

Leave-one-out

95.0

94.5

5000 (75% training /
25% testing)
Leave-one-out

92.4

87.6

93.2

86.5

82.1

86.2

84.0

90.0

81.0

86.8

81.6

60.6

100

95.0

91.5

86.7

78.9

93.0

86.3

81.9

86.0

96.1

75.0

95.0

90.5

83.3

93.0

85.7

95.0

96.6

96.6

93.8

93.3

86.6

82.3

86.3

Accuracy Sensitivity Specificity
(%)
(%)
(%)

30 (10 folds)

30 (10 folds)

10 (10 folds)

10 (10 folds)

10 (10 folds)

10 (10 folds)

Repetition (cross
validation)

*This paper by Cuingnet et al. compares ten methods and the best performance is shown here.

Zhang et al., 2011(Zhang, et
al., 2011)
Zhang et al., 2011(Zhang, et
al., 2011)
Zhang et al., 2011(Zhang, et
al., 2011)
Zhang et al., 2011(Zhang, et
al., 2011)
Hinrichs et al., 2011(Hinrichs,
et al., 2011)
Hinrichs et al., 2011(Hinrichs,
et al., 2011)
Magnin et al., 2009(Magnin,
et al., 2009a)
Kloppel et al., 2008(Kloppel,
et al., 2008)
Kloppel et al., 2008(Kloppel,
et al., 2008)
Kloppel et al., 2008(Kloppel,
et al., 2008)
Walhovd et al.,
2010(Walhovd, et al., 2010b)
Walhovd et al.,
2010(Walhovd, et al., 2010b)
Cuingnet et al.,
2011*(Cuingnet, et al., 2011)
Huang et al., 2000(Huang, et
al., 2000)
Proposed Study

Authors

Table 6: Performance comparison of different methods

2.4

Discussion

The rank of the variables derived using the proposed feature selection process adds
credence to the merits of combining structural MRI measures with the cognitive measure
of MMSE for classifying AD, aMCI and non-aMCI from CN. Moreover, on the basis of
the incremental error analysis, the top-ranked features as determined define the optimal
decisional space on which group classifications (AD vs. CN, aMCI vs. CN and naMCI vs.
CN) are carried out. It may be argued that the rank as derived in this study may vary as
the size of the dataset under consideration is changed. A test trying to rerun the ranking
of the variables by reducing the dataset size was done and recorded in Table 5,
demonstrating that the rank doesn’t change even when the dataset size is reduced by 50%.
This indicates that the combination of variables found in this study is reliable,
reproducible, and statistically meaningful even under a smaller subset of the data.

It can also be argued that incremental error analysis doesn’t cover all the possible
combinations of the significant variables as indicated in Table 2 and Table 3; thus there
might be a combination that was not considered in the analysis that could have produced
a better result. For AD vs. CN, there are 28 significant variables. All possible
combinations are in the form of C (where n means the 28 significant variables, which
could be combined 2 at a time, 3 at time etc. for different values of k, yielding different
multidimensional decisional spaces). Such an exhaustive attempt at assessing all these
combinations variables is not only unyielding, but rather unnecessary in light of the
statistical meaningfulness which supports the proposed method of ranking these variables.
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As can be observed from Figure 3, there were situations where performance increases
slightly as other lower-ranked variables are considered. For example, when variable 8 is
considered, the accuracy increases from 90.2% to 90.5% by 0.3% indicating that variable
8 does increase the classification performance and therefore should be considered as an
added dimension in the decisional space. However, this could be due to the randomness
of the subjects during the cross validation process using the SVM classifier. A slightly
more favorable distribution of subjects can yield a relatively improved result.
Consequently, the random distribution of the subject data was the primary reason for
averaging the results of a large number of randomized runs (50) of the program for each
experiment. On the other hand, the rank of the variable, especially lower-ranked variables,
may suffer much variation from one dataset to another as they may intrinsically have very
close mean differences identified by statistical test with close p values between the two
groups under comparison. However this doesn’t affect the meaningfulness of those very
top-ranked variables. Furthermore, even though ranking variability may be observed, the
top 3 ranked variables do not change. It should also be noted that determining the correct
rank of the lower-ranked variables cloud be difficult and in some cases impractical due to
the high unpredictability seen in these variables from one dataset to another.

The projection of subjects in the testing set on a decisional space based on the three
aforementioned top-ranked variables for AD vs. CN is shown in Figure 5. A total of 5
misclassifications were observed which included 3 CN and 2 AD subjects. It can be seen
that AD and CN groups are generally separable as they form two clearly distinct clusters,
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especially the CN group, which is a denser cluster. This clustering outcome adds further
credence to the importance of these three dimensions (variables).

Even though the use of MMSE score as a cognitive measure is limited in the sense that
individuals may experience decline that is not captured, the preliminary results of this
study suggests that MMSE improves classification results when combined with MRI
measures. This implies that other neuropsychological tests such as verbal fluency test and
delayed paragraph recall test may also contain complimentary information for improving
classification of AD (or MCI) when used in conjunction with MRI measures.

Figure 5: A specific case displaying the distribution of the half subject population of the
testing set in the context of the first three principle variables. Out of the 93 subjects shown
and used for testing the SVM classifier only 5 misclassifications are seen which are shown
by solid dots. This is a typical case of classification approach for AD vs. CN.
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From Table 6, a previous study using MMSE showed an accuracy of 92.3% for
classifying AD from CN (Zhou, et al., 2014a). However, this study lacked the analysis for
the MCI group. Table 6 indicates that the proposed technique using MMSE and MRI can
yield competitive classification performance as those using two or more imaging
modalities or biomarkers.
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CHAPTER 3
3. SIGNIFICANCE OF NORMALIZATION ON ANATOMICAL MEASURES

3.1

3.1.1

Methodology

Subjects

A total of 189 subjects are included in this study as shown in Table 7. All participants are
from the Wien Center for Alzheimer’s Disease and Memory Disorders with the Mount
Sinai Medical Center, Miami Beach, FL, USA. All subjects have taken the Folstein MiniMental State Examination(Folstein, et al., 1975) with a minimum score of 15 out of 30.
The study was approved by the Mount Sinai Medical Center Institutional Review Board
with informed consent provided by the subjects or legal representatives.

Table 7: Demographic and neuropsychological characteristics of subjects
Age

Female/Male

MMSE

CN (n = 129)

72.9 ± 6.4

92 / 37

28.7 ± 1.4

AD (n = 60)

79.5 ± 6.9

34 / 26

22.6 ± 3.4

p

< 0.001

ns

< 0.001

Data Presented as mean ± S.D. where applicable. Two-way Student t test was used to test for age
and MMSE and Fisher’s exact test was used to test for gender.

All subjects had: (1) a neurological and medical evaluation by a physician; (2) a full
battery of neuropsychological tests (Duara, et al., 2010), according to the National
Alzheimer’s Coordinating Center protocol, and the following additional tests: the Three-
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Trial Fold Object Memory Evaluation (Fuld, 1982) and the Hopkins Verbal Learning
Test ; as well as (3) a structural volumetrically acquired MRI scan of the brain. The
Clinical Dementia Rating Scale (CDR-sb) was used as the index of functional ability, and
the MMSE was used as the index of cognitive ability. The cognitive diagnosis was made
using a combination of the physician’s diagnosis and neuropsychological diagnosis. The
etiological diagnosis was made by the examining physician. The diagnosis of CN
required that the physician’s diagnosis was CN and no cognitive test scores were ≥1.5 SD
below age- and education-corrected means. A probable AD diagnosis required a dementia
syndrome and the National Institute of Neurological Disorders and Stroke
(NINDS)/Alzheimer’s Association criteria for AD (McKhann, et al., 1984).

3.1.2

Feature Extraction and Incremental Error Analysis

All the variables in a given model are first ranked based on statistical significance
between AD and CN. Following this ranking, an incremental error analysis is used
whereby the SVM classifier is trained and tested adding a single variable at a time to the
classifier to determine the combination of top-ranked variables that yield the optimal
classification outcome. This rigorous blind feature selection technique differs from others
as it does not rely on prior assumptions of regions of interest (ROI) and thus assigns
equal weights to all the variables. The above process was performed on all models to
compare their discriminative power and consequently identify the optimal model for AD
classification. It should be noted that although regional atrophy among AD patients is
what is generally sought, the statistical test considers both cases of atrophy and
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enlargement of these specific brain regions, since volumetric enlargement can be
experienced in regions like the ventricles, which has been shown to be important in
differentiating AD and its prodromal stages (Apostolova, et al., 2012; de Leon, et al.,
1989a; Thompson, et al., 2004b).

3.1.3

Normalization and Classification Experiment

To explore the effect of normalization on the classification performance, MRI measures
are normalized by the widely accepted morphometric measures like intracranial volume
(ICV) for regional subcortical volumes, ICV and mean cortical thickness of the subject
for regional cortical thickness, and ICV and the total surface area of the subject for
regional surface area. A summary of the normalization measures is presented in Table 8.
ICV is derived from the MRI and is one among the 10 morphometric statistics obtained
by the Freesurfer pipeline. Mean cortical thickness is estimated by averaging the
thickness of all the 68 regions of the brain for each subject. Similarly, total surface area is
the sum of all regional surface area measures for a given subject.

Table 8: Normalization Measures
MRI Measure

Morphometric Normalization Measure

Subcortical volumes (SV)

Intracranial Volume (ICV)

Cortical Thickness (CT)
Surface Area (SA)

Intracranial Volume (ICV)
Mean Cortical Thickness
Intracranial Volume (ICV)
Total Surface Area
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Classification was performed using a support vector machine (SVM) classifier, which is
shown to be effective as a classification tool for AD (Kloppel, et al., 2008; Lopez, et al.,
2009; Magnin, et al., 2009a). The kernel function of the SVM used for this particular
study is the Gaussian Radial Basis Function kernel (rbf) with a scaling factor (σ) of 3. All
the classification results reported here are based on a 5-fold cross validation process.
Each classification experiment was run 50 times, the results of which are averaged to
evaluate the performance in terms of accuracy, sensitivity, specificity and precision.

3.2
3.2.1

Results and Discussions
Classification Performance and Model Selection

Single measure models using only one type of the regional measures or MMSE were
created for subcortical volume, cortical thickness, surface area and neuropsychological
data (MMSE) for both raw and normalized data. Hierarchical models were also created
by combining two or more of the single models for both raw and normalized data.
Feature selection based on statistical testing was performed for all the models created.
The results of models with raw data are shown in Table 9 and the results for models with
normalized data are shown in Table 10. All the results display an average of 50 runs with
minimum and maximum values shown in parentheses.

Results of the different models are highly consistent as results of the 50 independent
repetitions of classification fall within a small range as shown by the minimum and
maximum values in Table 9 and Table 10. This small range is a clear indication of the
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replicability of results, both essential attributes in any classification process. These results
also indicate that MMSE is an important factor that should be included in the
classification process. Inclusion of MMSE with other measures improves significantly
the classification results. For example in the case of the optimal model, hierarchical
model using subcortical volumes (SV) with the inclusion of MMSE resulted in an
improvement of 9.2% as compared to using SV alone. In retrospect, an average
improvement of 13.3% is seen on comparing analogous models with and without MMSE
when using raw data and 12.8% when using normalized data.

The classification results given in Table 9 and Table 10 show that cortical thickness
should be normalized by either the mean thickness of all the measured regions or ICV,
while normalizing subcortical volumes to ICV doesn’t have any significant effect. In a
recent study, Westman et al. explored the normalization effect of regional MRI measures
using orthogonal partial least square to latent structures (OPLS) models and concluded
that both cortical thickness and subcortical volumes should not be normalized (Westman,
et al., 2013).

Both studies thus suggest that subcortical volumes should not be

normalized to ICV. The divergence is seen in the normalization of cortical thickness.
This could be potentially explained by the difference of the technique being used.
Westman and his colleagues used an all variables inclusive model (OPLS) and the
proposed method is feature selection based. The cause might be that normalization of
cortical thickness brings down the variation of all the regions in general which OPLS
model rely on but enhance variation in some specific regions that feature selection
method might have selected. Thus, normalization of cortical thickness depends on the
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processing technique used. Also, the divergence can be due to the subtle differences in
the data that is used for the study.

Table 9: Classification performances on raw data
Model
MMSE
Subcortical
volume (SV)
Cortical thickness
(CT)
Surface area (SA)
Average

Accuracy

Sensitivity

Specificity

Precision

88.3
(87.3-89.4)
83.1
(81.5-85.2)
77.7
(76.2-78.9)
71.4
(68.3-73.6)

81.0
(76.7-81.7)
77.9
(75.0-80.0)
74.8
(73.3-76.7)
58.7
(53.3-65.0)

91.6
(91.5-94.6)
85.6
(83.0-88.4)
79.0
(77.4-80.7)
77.2
(73.6-79.8)

82.6
(81.3-87.6)
72.6
(69.2-77.6)
63.0
(59.9-68.0)
55.0
(51.9-58.9)

80.1

73.1

83.4

68.3

92.3
(90.5-93.1)
91.4
(90.4-92.6)
88.6
(86.3-89.5)
83.1
(81.5-85.2)
83.1
(81.5-85.2)
92.3
(90.5-93.1)

88.2
(85.0-90.7)
85.3
(83.3-88.3)
76.3
(71.7-78.3)
77.9
(75.0-80.0)
77.9
(75.0-80.0)
88.2
(85.0-90.7)

94.2
(92.3-95.3)
94.2
(93.0-95.4)
94.3
(91.5-95.4)
85.6
(83.0-88.4)
85.6
(83.0-88.4)
94.2
(92.3-95.3)

88.3
(85.1-90.5)
87.8
(85.1-90.3)
87.1
(81.4-89.9)
72.6
(69.2-77.6)
72.6
(69.2-77.6)
88.3
(85.1-90.5)

88.5

82.3

91.4

82.8

Hierarchical Model
MMSE + SV
MMSE + CT
MMSE + SA
CT + SV*
SA + CT + SV*
MMSE + SA +
CT + SV**
Average

*The results of these models are the same as model of ‘SV’ since the variables extracted for the
decisional space are the same as that for ‘SV’ model. ** This model gives identical results as the
model of ‘MMSE+SV’ since variables extracted for the decisional space are the same as that for
‘MMSE+SV’
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Table 10: Classification performances on normalized data
Model

Accuracy

Sensitivity

Specificity

Precision

Subcortical volume
(SV)

83.5
(82.0-84.7)

74.4
(71.7-76.7)

87.7
(95.3-90.0)

75.2
(72.0-79.0)

Cortical thickness
(CT)

79.0
(77.8-80.4)

78.8
(75.0-81.7)

79.2
(77.5-80.6)

64.5
(61.8-87.4)

CT (Mean)*

78.9
(77.2-80.5)

78.4
(75.0-81.7)

79.2
(75.7-80.7)

64.6
(60.9-68.4)

Surface area (SA)

72.3
(68.8-75.2)

42.6
(35.0-48.3)

86.1
(82.1-89.2)

60.4
(50.8-65.3)

SA (Area)**

72.6
(70.3-75.1)

61.2
(58.3-63.3)

77.9
(75.1-81.4)

57.4
(52.9-61.8)

77.3

67.1

82.02

64.4

MMSE + SV

91.7
(90.0-93.1)

85.8
(81.7-88.3)

94.5
(93.1-95.4)

88.2
(85.0-90.7)

MMSE + CT

91.5
(89.4-93.2)

86.9
(81.7-90.0)

93.6
(90.8-96.1)

87.2
(82.7-90.9)

MMSE + CT
(Mean)*

90.3
(89.2-91.1)

90.8
(89.6-91.7)

90.1
(88.2-91.7)

81.4
(78.5-83.9)

MMSE + SA

88.3
(87.3-88.9)

80.9
(76.7-81.7)

91.7
(91.4-93.8)

82.7
(81.1-86.1)

MMSE + SA
(Area)**

88.6
(86.8-89.9)

80.9
(75.0-78.3)

94.2
(92.2-95.4)

86.9
(84.6-89.5)

CT + SV

83.1
(80.9-84.2)

75.8
(73.3-76.7)

86.5
(84.4-88.4)

73.3
(70.2-76.8)

CT + SA + SV

83.4
(81.0-85.7)

78.0
(75.0-80.0)

85.9
(83.0-89.1)

73.2
(68.3-69.4)

MMSE CT + SA +
SV

91.7
(90.4-92.6)

86.0
(83.3-90.0)

94.4
(93.7-95.4)

88.4
(86.5-90.2)

88.6

83.1

91.3

82.7

Average
Hierarchical Model

Average

* Scaled by the mean thickness of the all the thickness measures
**Scaled by the total area of the all the measures
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Since some models have very close performance in terms of the 4 recorded performance
metrics (accuracy, sensitivity, specificity and precision), models that give more than 90%
accuracy are considered as good models and are highlighted in gray in Table 9 and Table
10. Inclusion of additional measures does not guarantee a significant performance
enhancement. A tradeoff exists between models with some displaying better accuracy at
the cost of sensitivity and vice versa. In terms of accuracy, the model of ‘MMSE + SV’ is
the best; whereas in terms of sensitivity, the model of “MMSE + CT (Mean)” is more
appropriate.

A comparison of classification performance with recent studies in literature is provided in
Table 11. The results indicate that the proposed technique using MMSE and MRI can
yield competitive classification performance as those using two or more imaging
modalities or biomarkers. As Westman and his team described the concept of costbenefits to assess the increased cost of combining biomarkers as the potential limitation
(Westman, et al., 2012b), the proposed approach has the advantage of low cost yet high
accuracy. In addition, the results in this study are based on a larger cohort than most other
studies in Table 11.
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MRI
MRI + CSF
MRI
MRI + MMSE

(Walhovd, et al., 2010b)

(Walhovd, et al., 2010b)

*(Cuingnet, et al., 2011)

Proposed Study

Private(129/60)

ADNI(162/137)

ADNI(42/38)

ADNI(42/38)

Group III (33/57)

Group II (14/14)

Group I (20/20)

Private(16/22)

ADNI(51/52)

ADNI(51/52)

ADNI(51/52)

50 (5 folds)

- (2 folds)

N/A

N/A

Leave-one-out

Leave-one-out

92.3

N/A

88.8

82.5

81.1

92.9

95.0

94.5

5000 (75% training /
25% testing)
Leave-one-out

92.4

87.6

93.2

86.5

82.1

86.2

Accuracy
(%)

30 (10 folds)

30 (10 folds)

10 (10 folds)

10 (10 folds)

10 (10 folds)

10 (10 folds)

Repetition (cross
validation)

*This paper by Cuingnet et al. compares ten methods and the best performance is shown here.

MRI

MRI

(Magnin, et al., 2009a)

(Kloppel, et al., 2008)

MRI+PET+CSF+AP
OE+Cognitive Scores

(Hinrichs, et al., 2011)

MRI

MRI +PET

(Hinrichs, et al., 2011)

(Kloppel, et al., 2008)

MRI, PET, CSF

(Zhang, et al., 2011)

MRI

ADNI(48/66)

PET

(Zhang, et al., 2011)

(Kloppel, et al., 2008)

ADNI(48/66)

CSF

(Zhang, et al., 2011)

ADNI(51/52)

MRI

(Zhang, et al., 2011)

Source of Data
(AD/CN)

Imaging Modality/
Biomarkers

Authors

Table 11: Performance comparison of different methods

88.2

81.0

86.8

81.6

60.6

100

95.0

91.5

86.7

78.9

93.0

86.3

81.9

86

Sensitivity
(%)

94.2

95.0

90.5

83.3

93.0

85.7

95.0

96.6

96.6

93.8

93.3

86.6

82.3

86.3

Specificity
(%)

3.2.2

Univariate Analysis of Anatomical Measures

This section investigates how normalization affects the statistical significance of the
variables that are used in the classification model. The effect of normalization can be
determined by observing the change in the significance of the MRI measures when
normalization is carried out. To illustrate the effect of normalization approaches on the
statistical significance of region of interests (ROIs), univariate analysis was performed
for subcortical volumes as shown in Table 12, and on surface area for left and right
hemisphere respectively as shown in Table 13, and on cortical thickness for left and right
hemisphere respectively as shown in Table 14. Univariate analysis was created for the
two hemispheres separately for both cortical thickness and surface area in order to inspect
the possible pattern differences between left and right hemisphere. In Table 12 – Table
14, the regions of the brain for which the significance of the variable differ between raw
and normalized data are bolded. Please note that only those regions which show such a
behavior for both the normalization techniques are highlighted in Table 13 and Table 14 .

Table 12 shows that ICV normalization to the subcortical volumes does not change the
statistical significance of the variables, particularly for the top-ranked variables;
suggesting that normalizing subcortical volumes with ICV might not be necessary, which
is consistent with the conclusion made previously that subcortical volumes are not
recommended to be normalized to ICV as seen from the results provided earlier in Table
13 and Table 14.
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More importantly, subcortical volumes and cortical thickness show symmetry between
the left and right hemispheres for the top-ranked variables as shown in Table 12 – Table
14. In other words, regions of the brain that are significant towards classification of AD
subject are symmetrically located on either lobes of the brain. A typical example is seen
in the top 5 ranked regions according to subcortical volumes which include both the right
and left hippocampus and the right and left inferior lateral ventricles.

However, Table 13 shows that for the surface area there is almost no symmetry at all
between the left and right hemispheres for both the raw and normalized data. This could
possibly be explained by the fact that all variables found to be significant using surface
area possess a p-value close to the significance level threshold (0.05). Another point to be
noted is that for both raw and normalized data, surface area has a smaller number of
significant variables and relatively high p-values, indicating that surface area may be
generally regarded as a weaker biomarker of AD atrophy than the other two measures
which are SV and CT.
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< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001

< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001
< 0.00001

Left Inferior Lateral Ventricle

Left Hippocampus

Left Amygdala

Right Inferior Lateral Ventricle

Cortex Volume

Left Hemisphere Cortex Volume

Right Hemisphere-Cortex Volume

Total Gray Volume

3rd Ventricle

Right Amygdala

Right choroid plexus

Right Lateral Ventricle

Left Lateral Ventricle

p values

ICV

< 0.00001

Raw

Right Hippocampus

Volumes

5th Ventricle

Optic Chiasm

Subcortical Gray Volume

Non-White Matter Hypo-Intensities

Left Thalamus Proper

Right Ventral Diencephalon

Cerebral Spinal-Fluid(CSF)

Left Accumbens area

White Matter Hypo-Intensities

Corpus Callosum Middle Posterior

Right Thalamus Proper

Corpus Callosum Posterior

Right Accumbens area

Corpus Callosum Middle Anterior

Volumes

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.05

< 0.01

< 0.01

ICV

< 0.05

< 0.01

< 0.05

< 0.01

ns

ns

< 0.00001

< 0.001

< 0.0001

< 0.01

< 0.01

< 0.01

< 0.01

< 0.001

p values
< 0.0001

Raw

Table 12: Univariate analysis of subcortical volumes using different normalization approaches for AD vs. CN⃰

Table 13: Univariate analysis of surface area for left and right hemisphere*
Surface area
Normalization

Left Hemisphere

Right Hemisphere

Raw

ICV

Total
area

Raw

ICV

Total
area

Bankssts

< 0.01

< 0.05

< 0.001

ns

ns

ns

Frontalpole

< 0.01

< 0.05

< 0.05

ns

ns

ns

Paracentral

< 0.05

< 0.01

< 0.01

ns

ns

ns

Transversetemporal
Lingual

ns

< 0.01

< 0.01

ns

ns

ns

ns

ns

< 0.01

ns

ns

ns

Postcentral

ns

< 0.01

< 0.01

ns

ns

ns

Insula

ns

< 0.05

< 0.01

ns

ns

ns

Cuneus

ns

ns

< 0.05

ns

ns

< 0.05

Temporalpole

ns

ns

ns

< 0.01

< 0.01

< 0.001

Superior-frontal

ns

< 0.05

< 0.01

ns

< 0.05

< 0.01

Precentral

ns

ns

< 0.05

ns

< 0.05

< 0.01

Fusiform

ns

ns

< 0.05

ns

ns

< 0.01

Inferiortemporal

ns

ns

ns

ns

ns

< 0.01

Inferiorparietal

ns

ns

ns

ns

ns

< 0.05

*Two-way Student t test is used for univariate analysis with a significant level of 0.05 for p-value.

The regions of the brain which are determined to be statistically significant are displayed
in Figure 6 through Figure 9. Figure 6 represents the top 5 significant subcortical
volumes based on raw data. Figure 7 and Figure 8 represent the cortical regions of the
brain which are found to be significant for AD classification using cortical thickness (CT)
and surface area (SA) respectively on raw data. Figure 9 illustrates the change that is seen
in the significant regions of the brain when surface area normalized to the total surface
area is used as a measure, as compared to raw data as shown in Figure 8.
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One interesting finding about cortical thickness in Figure 7 is that most of the significant
regions belong to the temporal lobe, suggesting that the temporal lobe undergoes the most
significant thickness change. This is consistent with the result found by some other
studies (Dickerson, et al., 2009b; Rombouts, et al., 2000), particularly the finding that
large degree of thinning of temporal cortical thickness seen in AD while thinning is
relatively reserved in normal aging(Dickerson, et al., 2009b). The non-symmetric atrophy
pattern of surface area can be easily observed anatomically in Figure 8 and Figure 9.
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Table 14: Univariate analysis of cortical thickness for left and right hemisphere*
Cortical thickness
Normalization

Left Hemisphere

Right Hemisphere

Raw

ICV

Mean CT

Raw

Superiortemporal

< 0.00001

< 0.00001

< 0.00001

< 0.00001

< 0.00001 < 0.00001

Entorhinal

< 0.00001

< 0.00001

< 0.00001

< 0.00001

< 0.00001 < 0.00001

< 0.00001

< 0.00001

< 0.00001 < 0.00001

Inferiortemporal

< 0.00001
< 0.00001

< 0.00001
< 0.00001

< 0.01

< 0.00001

< 0.0001

< 0.01

Middletemporal

< 0.00001

< 0.00001

< 0.05

< 0.00001

< 0.0001

< 0.05

Parahippocampal

< 0.00001

< 0.00001

< 0.01

< 0.00001

< 0.00001

< 0.05

Fusiform

< 0.00001

< 0.0001

< 0.001

< 0.00001

< 0.001

< 0.01

Supramarginal

< 0.00001

< 0.0001

ns

< 0.00001

< 0.001

ns

Lateralorbitofrontal

< 0.00001

< 0.001

ns

< 0.00001

< 0.01

ns

Parsorbitalis

< 0.00001

< 0.001

ns

< 0.00001

< 0.001

ns

Bankssts

< 0.00001

< 0.0001

ns

< 0.00001

< 0.001

ns

Superiorfrontal

< 0.00001

< 0.001

< 0.05

< 0.00001

< 0.001

ns

Parsopercularis

< 0.00001

< 0.001

ns

< 0.00001

< 0.01

ns

Insula

< 0.00001

< 0.001

< 0.01

< 0.00001

< 0.001

< 0.01

Rostralanteriorcingulate < 0.00001
< 0.00001
Isthmuscingulate

< 0.01

< 0.05

< 0.00001

< 0.001

< 0.001

< 0.01

ns

< 0.00001

< 0.001

ns

Inferiorparietal

< 0.00001

< 0.001

< 0.05

< 0.00001

< 0.001

ns

Transversetemporal

< 0.00001

< 0.001

ns

< 0.001

< 0.05

ns

Caudalanteriorcingulate

< 0.00001

< 0.01

ns

< 0.00001

< 0.01

ns

Parstriangularis

< 0.00001

< 0.01

< 0.05

< 0.00001

< 0.01

< 0.01

Rostralmiddlefrontal

< 0.00001

< 0.05

< 0.0001

< 0.00001

< 0.05

< 0.01

Caudalmiddlefrontal

< 0.00001

< 0.01

ns

< 0.00001

< 0.01

ns

Posteriorcingulate

< 0.00001

< 0.01

ns

< 0.00001

< 0.01

ns

Precuneus

< 0.00001

< 0.01

ns

< 0.00001

< 0.01

ns

Medialorbitofrontal

< 0.00001

< 0.05

ns

< 0.001

ns

ns

Precentral

< 0.00001

< 0.05

< 0.05

< 0.0001

< 0.05

ns

Frontalpole

< 0.0001

< 0.05

ns

< 0.01

ns

ns

Postcentral

< 0.01

ns

< 0.00001

< 0.01

ns

< 0.00001

Superiorparietal

< 0.01

ns

< 0.00001

< 0.01

ns

< 0.0001

Lateraloccipital

< 0.01

ns

< 0.00001

< 0.05

ns

< 0.00001

Lingual

< 0.05

ns

< 0.00001

< 0.01

ns

< 0.00001

Paracentral

< 0.05

ns

< 0.01

< 0.01

ns

< 0.01

Pericalcarine

ns

ns

< 0.00001

ns

ns

< 0.00001

Cuneus

ns

ns

< 0.00001

ns

ns

< 0.00001

Temporalpole

ICV

Mean CT

*Two-way Student t test is used for univariate analysis with a significant level of 0.05 for p-value.
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Inferior Lateral Ventricles

Hippocampi

Left Amygdala

Figure 6: Representation of the top 5 significant subcortical volumes based on raw data in
Table 12. (A) Superior view (B) Lateral view

Lateral View

Medial View

(A)
Superiortemporal

(B)
Middletemporal

Inferiortemporal

Entorhinal

Temporalp

Figure 7: Representation of the top 5 significant cortical thickness based on raw data in
Table 14. (A) Left hemisphere (B) Right hemisphere
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Lateral View

Medial View

(A)
Paracentral

(B)
Bankssts

Frontal Pole

Temporalpole

Figure 8: Representation of all significant surface area based on raw data in Table 13. (A)
Left hemisphere (B) Right hemisphere

Lateral View

Medial View

(A)
Bankssts
Lingual

Frontal
Postcentral

(B)
Paracentra

Insula

Fusiform

Cuneus

Temporalpole
Inferiorparietal

Superiorfrontal
Inferiortemporal

Precentral

Figure 9: Representation of all significant surface area based on total-area normalized
data on Table 13. (A) Left hemisphere (B) Right hemisphere
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3.2.3

Spatial Distribution of Subjects Under the Best Model

Model of “MMSE + SV” without normalization gives the highest classification accuracy
which utilizes the top 3 variables found within the model (i.e. MMSE, right-hippocampus
volume and left-inferior-lateral-ventricle volume). One typical distribution of the data
points for this classification model is plotted in Figure 10 to show the clustering
characteristics of the data when MMSE and subcortical volumes are employed. Using
this optimal decisional space, it can be observed that all the normal subjects are grouped
into a very compact cluster, whereas AD subjects are more sparsely distributed in context
of these dimensional parameters. This indicates the complex pattern of atrophy
undergoing among the AD patients, which renders the classification task extremely
difficult.

Figure 10: Representation of the whole dataset for the model of MMSE + subcortical
volume, for a typical classification run under this model
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3.2.4

Model Efficiency Estimation and Normalization

Variation in measures can come from many sources, including variation due to AD
atrophy (σ

), which is of primary interest for classification purposes, as well as other

variation noise (σ ) like individual difference in brain size, structure of brain regions,
MRI measure error, region segmentation error, atrophy due to normal aging and
resistance to brain atrophy (e.g. cognitive reserve). Generally, the total variance can be
described as follows:

σ

where σ

=σ

is the total variance of dataset, σ

+σ

(3.1)

stands for variance due to AD atrophy

and σ is the variance due to what is termed here as an overall source of noise. Also,
discriminative power of a model depends on the amount of variance due to AD atrophy
captured by the model used in contrast to the variance due to noise. A relevant term
called discriminative power (Dp) can be estimated using Equation (3.2).

Dp =

where σ

(3.2)

is an estimate of the variance due to AD atrophy captured by the model, and

σ stands for the estimated variance due to noise captured by the model.
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Our results thus show that normalization in general does not enhance the classification
performance significantly, which could be explained through Eq. 2 which shows that
normalization does bring down correlated noise (σ ) experienced through brain size
difference, but it also lowers down the correlated variance due to AD atrophy (σ

). A

supporting finding of this assumption is that proportional volumes of the superior
temporal cortex, expressed as a proportion of total cerebral volume was significantly
different between females and males (Harasty, et al., 1997), which exemplifies the fact
that normalization may be intrinsically biased. A similar finding by Barnes et al. is that
normalization of all volumes by head size is not adequate due to their non-proportional
relationship (Barnes, et al., 2010). Also Ross et al. found that males generally have a
larger overall brain size than female, and males have larger cerebral cortical volumes than
females except for left parietal(Carne, et al., 2006), thus normalization will at least bring
in noise to the regions in left parietal as the regions in that area for males have a smaller
size but normalized to a larger head size. However, the Dp value could still serve as a
measure of a model’s performance if relevant sources of the variance are known and are
quantifiable, which is not the case in most practical scenarios.
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CHAPTER 4

4. CLASSIFICATION AND PREDICTION BY PROPOSED EFFECTIVE MEAN
INDICATOR

4.1

Background

The features extracted from biomarkers are often analyzed most often using various
multivariate data analysis method such as principal component analysis (PCA) (López, et
al., 2009; Nobili, et al., 2008), partial least square (PLS) (Higdon, et al., 2004; Ramírez,
et al., 2010), and orthogonal partial least squares (OPLS) as exemplified in (Westman, et
al., 2012a; Westman, et al., 2011b). The common objective of these techniques is to
project the data into a decisional space where the total variance or variance related to
class separation is maximized. Then linear or nonlinear using specific classifiers are then
determined to delineate the populations or groups under study (Chaves, et al., 2009a;
López, et al., 2009; Magnin, et al., 2009b; Zhou, et al., 2014d).

4.2
4.2.1

Methodology
Inclusion and Diagnostic Criteria

Only subjects from ADNI database with valid baseline MRI measures passing visual
quality control (QC) evaluation were included in this study (as of February 2014 on
ADNI website (https://ida.loni.usc.edu/login.jsp)). This has yielded a total of 543
qualified participants (CN = 139, EMCI = 220, LMCI = 108 and AD = 76). The
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demographics and clinical characteristics of all the participants are as shown in Table 15.

Table 15: Demographics and characteristics of all participants
CN

EMCI

LMCI

AD

p-value*

Number

139

220

108

76

-

Gender
(female/male)

74/65

101/119

50/58

32/44

†

Age

73.6 ± 6.0

69.9 ± 7.0

71.0 ± 7.6

75.1 ± 7.3

< 0.001

Years of
education

16.4 ± 2.5

16.0 ± 2.7

16.4 ± 2.7

16.0 ± 2.6

0.343

ADAS-11

5.8 ± 3.1

7.8 ± 3.5

11.4 ± 4.9

21.3 ± 7.3

< 0.001

ADAS-13

9.1 ± 4.5

12.4 ± 5.2

18.3 ± 7.1

31.9 ± 8.5

< 0.001

MMSE

29.1 ± 1.1

28.5 ± 1.5

27.6 ± 1.8

22.9 ± 2.0

< 0.001

0.194, 0.306, 0.153

Data are presented as mean ± standard deviation where applicable. ADAS-11 = 11-item
Alzheimer’s Disease Assessment Scale-cognitive subscale, ADAS-13 = 13-item Alzheimer’s
Disease Assessment Scale-cognitive subscale. *Unless otherwise noted, one-way ANOVA was
performed and p-values smaller than 0.05 are bolded. † Fisher’s exact test was performed for CN
vs. EMCI, CN vs. LMCI and CN vs. AD, respectively, and the corresponding p values are listed
in the same order.

Diagnostic criteria for CN, EMCI, LMCI and AD are as follows:
CN subjects: MMSE scores between 24 and 30 (inclusive), a clinical dementia rating
(CDR) score of 0, non-depressed, non-MCI, and non-demented; EMCI subjects: MMSE
scores between 24 and 30 (inclusive), a subjective memory concern reported by subject,
informant, or clinician, objective memory loss measured by education adjusted scores on
delayed recall of one paragraph from Wechsler Memory Scale Logical Memory II
(WMSLM II) (≥16 years: 9-11; 8-15 years: 5-9; 0-7 years: 3-6), a CDR of 0.5, absence of
significant levels of impairment in other cognitive domains, essentially preserved
activities of daily living, and an absence of dementia; LMCI subjects: Same as EMCI
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with a difference only in objective memory loss measured by education adjusted scores
on delayed recall of one paragraph from WMSLM II(≥16 years: ≤8; 8-15 years: ≤4; 0-7
years: ≤2); Mild AD Subjects: MMSE scores between 20-26 (inclusive), a CDR of 0.5 or
1.0, and meets NINCDS/ADRDA criteria for probable AD.

4.2.2

MRI Acquisition and Analysis

Original MRI scans were acquired from a variety of 3T scanners with protocols
individualized for each scanner, as defined in MRI protocols from ADNI website
(http://adni.loni.usc.edu/methods/documents/mri-protocols/). Cortical reconstruction and
volumetric segmentation of MRI scans were performed by applying FreeSurfer 5.1
(http://surfer.nmr.mgh.harvard.edu/) to T1 weighted MRI image (MPR or IRSPGR) in
NiFTI format which has been pre-processed by Mayo Clinic (gradient warping, scaling,
B1 correction and N3 inhomogeneity correction). The detailed technical procedures were
described in prior publications (Dale, et al., 1999b; Fischl and Dale, 2000; Fischl, et al.,
2002a; Fischl, et al., 2004a). In this study, FreeSurfer generated 271 applicable MRI
features (including 68 cortical volumes, 68 cortical thickness, 70 surface areas, 49
cortical volumes and 16 hippocampal subfields), and they were all reviewed by Mayo
Clinic for quality control.

4.2.3

Preprocessing of Data

In order to remove potential biases from further analysis, all MRI measures are
performed by linear regression tests against the affecting factors, namely age (as
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demonstrated in Table 15) and ICV. The measures with resulting p values less than 0.05
are adjusted based on Equation (4.1) as per Chiang et al.(Chiang, et al., 2011).

M = M

−G

∙ (V

Where M is the adjusted measure, M

−V

)−G

∙ (A − A )

is the unadjusted measure, V

subject ICV and age (in years), respectively; V

(4.1)

and A are the

and A are the means of ICV and

age for all the CN subjects, respectively. The gradients G

and G

are derived by a

region-specific linear regression against subject ICV and age based on all the
participants. This regression method also has the advantage that the order of regression
does not affect the results.

4.2.4

EMI Calculation

Theoretically, after correction, values of measures can be compared directly within the
same measure, meaning that the value difference of the same measure across different
subjects represents the true difference in that measure not due to head size difference or
age. In addition, the measure should be the same for the CN group and the actual variance
is supposedly due to measurement errors.

In this study, the mean of each measure are estimated by averaging each measure using
the training controls. And then all measures are normalized to these means, with the
expectation that values of the measure for controls will approximate 1, and values less
than 1 will be a measure of the severity of regional atrophy, typical of AD pathology.
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Student’s t-test with Bonferroni correction for multiple comparisons is performed to rank
all measures based on the corresponding p values. The mean of the top-ranked measures
are calculated and defined as EMI, and a threshold is defined so as to optimally separate
groups. Inclusion of measures such as ventricular volume, which increases in the
presence of brain atrophy, and is a good indicator of the severity of the disease
(Luxenberg, et al., 1987; Nestor, et al., 2008a; Zhou, et al., 2014d), requires the following
correction:

=2−M

M

where the value of M is the MRI measure before modification and M

(4.2)

is the same

measure after modification. (E.g., a value of 1.3 for the ventricles is converted to 0.7).

4.2.5

Validation and Incremental Error Analysis

Classifications for AD vs. CN, LMCI vs. CN and EMCI vs. CN are performed using the
proposed EMI-based method. The experiment is based on 10-fold cross validation,
meaning the whole dataset is equally divided into 10 subsets, each time one subset is
selected as testing data and the remaining 9 subsets as training data until all subsets have
been chosen as testing set once and only once. The two parameters needed for EMI
calculation are both generated during the training process, namely the mean of each
measure using the CN subjects and the determined top-ranked measures. In order to blind
the testing set of this information, these two parameters are based on only the training
data. The training process also finds an EMI threshold that separates the two compared
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groups with optimal performance. Then this obtained threshold is applied to the EMIs of
the testing subjects for prediction, and the performance in terms of accuracy, sensitivity
and specificity are recorded. The same experiments are repeated 50 times to get the
estimated average performance.

In this process, measures are deemed optimal if together they capture a comprehensive
pattern of atrophy that maximizes classification accuracy and yet they do not introduce
noise patterns that could negatively impact the classification outcome. Therefore, there
should be a specific number of top-ranked features selected that will yield the highest
performance instead of using all of them. To this end, an incremental error analysis is
designed to explore the number of top-ranked measures that should be included in the
EMI calculation so that the desired performance is achieved. The incremental error
analysis is employed by firstly using only the 1st top-ranked measure, and then each time
an additional next top-ranked measure is introduced in the EMI calculation until the last
measure in the rank is included. The general structure of the proposed EMI-based method
is schematically illustrated in Figure 11.
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Figure 11: General structure of the proposed EMI-based method

4.3
4.3.1

Results
Incremental error analysis

In context to the structure shown in Figure 11, the incremental error analysis is designed
to facilitate selection of the top-ranked measures that should be included in the
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calculation of EMI and the corresponding EMI thresholds for prediction. The incremental
error analysis is employed by starting from the top 1 measure and incrementally
including the next-ranked measure for EMI calculation. The corresponding optimal
separation thresholds for each inclusion of next-ranked measure are also recorded.
Realizing the exhaustive nature of this process, and since many lower-ranked measures
bear little information if any in the classification process, a Student’s t-test with
Bonferroni corrections for AD vs. CN, LMCI vs. CN and EMCI vs. CN using all subjects
was used to select a total of 120 significant measures for AD, 69 for LMCI and 7 for
EMCI. The accuracy as a function of the number of top-ranked measures included based
on 50 independent 10-fold cross-validated experiments is plotted in Figure 12. As the
measures are sorted in the training phase, which change during cross-validation, the rank
of features may alter slightly from time to time. Therefore the incremental error analysis
is designed to determine the number of top-ranked variables to be included. Figure
12shows that for each classification type there is a unique highest point, which decides
the number of top-ranked measures that should be included. Interestingly, for LMCI
classification, EMI using 30 top-ranked measures yielded the highest performance in
contrast with the top 6 for AD and the top 3 for EMCI. In addition, during the 50
repetitions of experiments for AD, the top 6 measures yielding the highest accuracy were
observed 44 times, demonstrating extremely robust patterns of this AD model for EMI
calculation. And 25 out of 50 times were observed for EMI using the 3 top-ranked
measures.
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(A)

(B)
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(C)

Figure 12: Incremental error analysis performance in terms of accuracy as a function of
the number of top-ranked measures included for (A) AD vs. CN. (B) LMCI vs. CN. (C)
EMCI vs. CN. The accuracy is the average obtained after 50 independent experiments
based on 10-fold cross validation with the maximal point highlighted with a big dot.
The performances denoted by the maximal point in Figure 12 are also summarized in
Table 16 in terms of accuracy, sensitivity and specificity. These results show that the
EMI method is very efficient in differential diagnosis of AD with an accuracy of 92.7%
for predicting AD. The numbers in parenthesis indicate the highest and lowest
performance obtained during the 50 repetitions, which as can be observed are of small
ranges of performance variation, confirming that the results are consistent.
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Table 16: Classification performance of the EMI-based method with the determined top
6, 31 and 3 features, as denoted by the maximal points shown in Figure 12 for AD vs.
CN, LMCI vs. CN and EMCI vs. CN, respectively
AD vs. CN
ACC
(%)

SEN

LMCI vs. CN
ACC
(%)

SEN

(%)

SPE
(%)

92.7

95.8

91.0

(91.293.1)

(93.696.3)

(89.291.4)

EMCI vs. CN
ACC
(%)

SEN

SPE

(%)

SPE
(%)

(%)

(%)

76.6

72.3

80.0

61.8

68.3

51.5

(74.878.5)

(69.474.3)

(77.683.5)

(58.565.5)

(62.372.7)

(41.860.3)

ACC = accuracy, SEN = sensitivity, SPE = specificity.

4.3.2

Histogram Plots, Boxplots and Scatter Plots of EMI

To investigate the separation efficiency of EMI for AD vs. CN, LMCI vs. CN and EMCI
vs. CN, the EMI were calculated for all subjects based on the number of top-ranked
measures found by the maximal points as shown in Figure 12. The descriptive statistics
of the EMI are presented in Table 17. As expected, the mean of EMI for EMCI group is
the highest and closest to that of CN, and AD is the lowest and furthest. Statistics tests
also show that the mean difference of EMI between AD and CN is more significant than
the other two cases as indicated by the p values in Table 16. It should also be noted that
the standard deviation of CN group for different classification types varies according to
the top-ranked measures that were used.

To better assess the separation efficiency of the EMI visually, histogram plots, boxplots
and scatter plots of the EMI are shown in Figure 13 -Figure 15, respectively. Besides,
these plots also have two lines depicting the largest and smallest thresholds resulting
from the 50 independent training experiments. The two extreme thresholds form a range
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of potential thresholds that may be obtained through the training process. The more
compact is the range, the more consistent the results would be. In other words, these
thresholds are like the separation boundaries of regular classifiers obtained repetitively
using partial subjects. If the boundaries are similar or close, it means the classifier is less
susceptible to population difference and is an indicator of robustness of the classifier.

Table 17: Descriptive statistics of the EMI
AD vs. CN

LMCI vs. CN

EMCI vs. CN

CN

AD

CN

LMCI

CN

EMCI

Mean of EMI

1.00

0.76

1.00

0.86

1.00

0.94

S.D.

0.087

0.095

0.059

0.120

0.098

0.120

Kurtosis

3.24

2.63

2.98

2.75

2.74

4.33

P value by
Student’s t-test
(Scale)
S.D. = standard deviation.

Figure 13 and Figure 15 jointly demonstrates that EMI-based method is efficient in
discriminating different stages of the disease with very compact threshold range (for AD
and LMCI in particular). In addition, the histogram in Figure 13 displays how the EMI of
subjects are distributed in terms of sub-ranges. As expected, the EMI distribution of AD
is more easily separable from CN distribution with less overlapping areas than LMCI and
EMCI. Figure 14 graphically depicts the EMI values through their quartiles. It can be
seen that the maximum of EMI among AD subjects is close to the median of EMI among
CN subjects and the minimum of EMI in CN group excluding an outlier lies almost in the
middle between the median and upper quartile of EMI among AD subjects.
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In

comparison, the EMI difference between LMCI (or EMCI) and CN groups are relatively
smaller but still notable. Figure 15 shows the scatter plots of EMI against subjects’ age
as 2-D representations of the data. Even though class separation is solely based on the
variation of EMI along the vertical axis, the age is used as the second dimension for
visual appreciation. As can be observed, EMI separates AD from CN efficiently with any
threshold in the determined range. Both the min and max thresholds separate LMCI from
CN decently as well. As expected, prediction of EMCI is more challenging as shown in
Figure 15C. It is worth noting that in Figure 15A, the EMI of AD subjects are quite stable
around the threshold, even more so than the EMI of CN subjects near the threshold range.
This observation is a strong indicator of the efficiency of EMI in identifying the pattern
of AD and complies with the results in Table 16 that prediction of AD yielded a higher
sensitivity of 95.8% than the specificity of 91.0%.
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Figure 13: Histogram plots of the EMI using previously validated number of top-ranked
measures for (top left) AD and CN. (top right) LMCI and CN. (bottom) EMCI and CN.
In order to present the separation thresholds obtained from the training process of the 50
independent experiments, the maximum and minimum thresholds are plotted as blue
lines.
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Figure 14: Boxplots of the EMI using previously validated number of top-ranked
measures for (top left) AD and CN. (top right) LMCI and CN. (bottom) EMCI and CN.
In order to present the separation thresholds obtained from the training process of the 50
independent experiments, the maximum and minimum thresholds are plotted as black
dots.
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(A)

(B)
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(C)

Figure 15: Scatter plots of the EMI using previously validated number of measures
against age for (A) AD vs. CN. (B) LMCI vs. CN. (C) EMCI vs. CN. In order to present
the separation thresholds obtained from the training process of the 50 independent
experiments, the maximum and minimum thresholds are plotted as blue lines.

Furthermore, Figure 15 also enables us to examine if there is a potential relationship
between subjects’ age and EMI, which in this case showed no evidence of such a
relationship. In addition, linear regression tests were also performed between subjects’
age and EMI, showing no significant relationship between them.

4.4

Discussion

In this study, we presented a new and robust EMI-based method to predict different
stages of AD, utilizing regional MRI measures normalized to the mean values based on
CN subjects. The cumulative difference of these regional measures from the mean value
of 1 is indicative of the severity of atrophy representative of Alzheimer pathology. We
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have shown in this study that the proposed EMI-method demonstrates superior and
consistent performance in predicting different stages of AD.

This new method has the advantage of simplicity and in converting MRI measures into
values that can be directly added and subtracted across measures without the assumptions
required of PCA and PLS methods (López, et al., 2009; Nobili, et al., 2008; Ramírez, et
al., 2010; Westman, et al., 2011b). These assumptions in PCA and PLS make the data
interpretation less intuitive, because the position and distance to the boundary of a testing
subject in the decisional space may be difficult to quantify, especially if the decisional
space is multi-dimensional. The advantage of EMI is that it provides a value that can be
intuitively interpreted as a measure of the severity of atrophy typically found in AD,
without requiring pretreatment of data using unit variance scaling (UVS) or other similar
methods to balance the variance of measures. In methods, such as PCA and PLS,
measures with large variance dominate and information-bearing measures with smaller
variance may be overwhelmed. Also, pretreatment of data like UVS may also hinder the
interpretation of the data while altering the variance of measures (van den Berg, et al.,
2006) and therefore the information related to class separation may be compromised. The
EMI-based method does not require such pretreatment of data so that all the raw
information is maximally retained.

Along with its simplicity in implementation, the EMI-based method has also
demonstrated a high level of predictability achieved using only the MRI biomarker as
shown in Table 16. Recent studies have combined different biomarkers to explore their
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complementary information (Davatzikos, et al., 2011; Fan, et al., 2008b; Hinrichs, et al.,
2011; Westman, et al., 2012a; Zhang, et al., 2011) and found that the combined
biomarkers has higher predictive power than using single biomarkers alone. Some of
these studies are selected for a performance comparison with the proposed EMI-based
method as shown in Table 18. The subjects in this study, derived from ADNI GO and
ADNI 2, has two well-defined MCI stages (EMCI and LMCI) while ADNI 1 has only
one as MCI stage.

The proposed EMI-based method is shown to be more effective in the prediction of AD
than any other methods, even though the other methods used multiple biomarkers. The
EMI method yielded a higher sensitivity than any other methods, thus improving the
classification of AD. Despite the difference in grouping of MCI subjects, the performance
of EMI method on LMCI classification is compared with the performance of MCI
classification in a recent and frequently cited study by Zhang et al.(Zhang, et al.,
2011).The proposed EMI-based method predicted LMCI using only MRI with an
accuracy of 76.6% (sensitivity: 72.3% and specificity: 80.0%), which is comparable to
the prediction of MCI using MRI, PET and CSF by Zhang et al.(Zhang, et al., 2011) with
an accuracy of 76.4% (sensitivity: 81.8% and specificity: 66.0%).

In addition, the highest and lowest performances of the 50 independent experiments, as
indicated in parenthesis in Table 18, show that EMI-based method has a consistent
performance with an even smaller range of variation than the method by Zhang et al.
Furthermore, as Westman et al. brought up the concern of cost in combining biomarkers
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in a prior study (Westman, et al., 2012a), the proposed method is an efficient and costeffective alternative for achieving high prediction performance without the extra cost for
using other biomarkers other than MRI.

4.4.1. Flexibility in Balancing Between Performances
As indicated in Figure 11, there are 3 parameters generated by the training process,
which are deemed essential for the prediction of the testing data. Among them, the first
one is the mean of each measure calculated using the CN subjects in the training set, to
which the testing data is normalized. The other two are generated by the incremental
error analysis, namely the number of top-ranked measures and the optimal EMI threshold
found during the training process. If a higher sensitivity for prediction is desired, a
threshold can be selected such that less AD subjects are misclassified despite the possible
cost of accuracy and/or specificity. In this study, the threshold in the training process was
determined such that performance (P) as defined below reaches maximum.

P = Accuracy ∗ 0.8 + Sensitivity ∗ 0.2 + Specificity ∗ 0.2

(4.3)

Equation (4.3) assigns different weights to the 3 measures of performance depending on
the 3 factors, which are really flexible depending on the demands on performance. For
example, the factors as used in this study assign more weight to accuracy than sensitivity
and specificity. This is another advantage of the EMI method that it allows for balancing
between accuracy, sensitivity and specificity in a simple and convenient way. For
example, if a more conservative diagnosis is required, a lower threshold will increase the
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sensitivity to some extent, and such balancing of performance can hardly be implemented
using other classifiers. Considering SVM classifiers as an example, which are frequently
used in studies of AD (Klöppel, et al., 2008; López, et al., 2009; Zhang, et al., 2011;
Zhou, et al., 2014c), when the decisional space is multidimensional, the decision
boundary has to move in every single dimension according to the distribution of training
data and there are many potential boundaries that may achieve the same goal such as a
higher sensitivity. More importantly, it is hard to justify which new boundary to use to
achieve the desired effect in prediction. Neither of these problems applies to the proposed
EMI-based method, as it makes its decision in only one dimension. In other words, it
integrates all the separation information into one dimension while achieving even higher
prediction performance in comparison to other methods.
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50 (10-fold)

- (7-fold)

10 (10-fold)

Repetitions
(cross
validation)
30 (10-fold)

86.0
(82.7-88.7)
93.0
(88.7-96.3)
83.3
(74.6-89.5)
88.5
(80.6-93.5)
95.8
(93.6-96.3)

86.2
(82.9 – 89.0)
93.2
(89.0-96.5)
87.0
(81.7-90.9)
91.8
(87.2-94.8)
92.7
(91.2-93.1)

MRI
MRI + PET + CSF
MRI
MRI + CSF
MRI

86.7

92.4

Sensitivity
(%)
78.9

Accuracy
(%)
87.6

MRI +PET
MRI+PET+CSF+APOE
+Cognitive Scores

Biomarkers

*The information of the highest and lowest performances is not available and thus left blank.

ADNI (139/76)

Proposed method

ADNI(51/52)

(Zhang, et al., 2011)

ADNI(111/96)

ADNI(48/66)

(Hinrichs, et al., 2011)*

(Westman, et al.,
2012a)

Subjects
(AD/CN)

Methods

91.0
(89.2-91.4)

94.6
(88.7-97.5)

90.1
(83.1-94.3)

93.3
(89.1-96.6)

86.3
(83.1-89.1)

96.6

93.8

Specificity
(%)

Table 18: Performance comparison of the proposed EMI-based method with other methods for predicting stages of
Alzheimer’s disease

4.4.2. Future Potential of EMI Method
As mentioned before, only the CN subjects in the training process were used to compute
the mean of each measure, which is then used to normalize all measures for both the
training and testing data. And in this study, there are 125 CN subjects in the training set
(10-fold cross validation). Even with the limited samples of CN subjects used in this
study, the prediction performance is already high and stable. If more CN subjects are
available, the resulting mean of each measure will be more accurate and it will also
improve the experiment performance. In addition, another goal of the training process is
to find the threshold that optimally separates the groups, which has also been shown to be
highly convergent, especially for AD and LMCI prediction as displayed in Figure 13
Figure 15 with 2 almost overlapped straight lines) depicting minimum and maximum
thresholds of the 50 independent experiments. The consistency of thresholds will again
be expected to improve along with the refinement of the mean of each measure because
they are found based on the subjects’ EMI, which is closely related to the measurements.

Overall, more accurate mean of each measure in the future may yield more accurate EMI
values and hence more consistent prediction results. Another merit of EMI-based method
is that the value of EMI itself is very intuitive, and a good representative in the level of
atrophy. This indicates its great potential in clinical trials by giving the physicians an
estimated level of the disease with those quantifiable values. And such a value may also
be potentially combined with some other screening test scores to generate an even more
information-bearing composite for diagnosis.
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CHAPTER 5

5. MULTIVARIATE ANALYSIS OF MRI AND PET (FDG AND 18F-AV-45)

5.1

Background

Subjects with AD suffer from progressive loss of cognitive functions, which are
associated with regional brain atrophy (Fox, et al., 1996). As a result, magnetic resonance
imaging (MRI) capable of capturing brain structure has been wildly used to analyze
structural change of the disease (Fox and Schott, 2004; Zhou, et al., 2014b). Regional
atrophy in hippocampus and amygdala (Laakso, et al., 1996; Laakso, et al., 1995a;
Thompson, et al., 2004a) , cortical thinning (Dickerson, et al., 2009a) and ventricular
enlargement (Thompson, et al., 2004a) were found significant related to anatomical
change of AD. It’s also been reported that extracellular beta-amyloid (A ) deposition
(Hardy and Allsop, 1991a) and tau protein abnormalities (Mudher and Lovestone, 2002b)
were the fundamental causes of the disease, which have made amyloid positron emission
tomography (PET) imaging modality popular as it’s able to evaluate amyloid plaque level
and hypometabolism of the brain, which contain discriminative information of AD
staging (Nordberg, et al., 2010b). There are three common PET imaging agents being
used, Fluorine-18-fluorodeoxyglucose (FDG), Florbetapir 18F (AV-45) and Pittsburgh
compound B (PiB). PiB and AV-45 work similarly as they both bind to A . While AV45 has much longer half-life time than PiB, which allows for more significant
accumulation of the tracer in the brain of AD subjects (Wong, et al., 2010). Researches
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using AV-45-PET have reported high A deposition among AD subjects in some specific
areas, such as precuneus, frontal and temporal cortices (Choi, et al., 2009; Wong, et al.,
2010). Recent studies using FDG-PET have reported significant correlation of dementia
severity

and FDG uptake level in defined areas, such as posterior cingulate,

temporoparietal, prefrontal association cortex and temporal cortex (Herholz, et al., 2002;
Piert, et al., 1996). FDG PET and AV-45 PET images are highly correlated while also
providing complimentary information (Hsiao, et al., 2012).

Orthogonal partial least square to latent structures (OPLS) is a supervised multivariate
data analysis method that has shown its efficiency in analyzing complex biological data
(Bylesjo, et al., 2006; Ray, 2012; Trygg and Wold, 2002; Westman, et al., 2012c;
Westman, et al., 2011b). For AD study, Westman et al. combined manual hippocampal
volume measurements with automated regional and global volume measures to
discriminate AD and MCI from controls. By comparing the discriminative powers of
these features, they reported that OPLS showed great potential in the prediction AD and
MCI and in the conversion from MCI to AD (Westman, et al., 2011b). They also
compared and combined MRI data from the European AddNeuroMed and ADNI using
OPLS method, and the results indicated that the two cohorts showed similar pattern of
atrophy and predictive power (between 80 and 90%) (Westman, et al., 2011a).

In

addition, they combined CSF and MRI measures for classification of AD and MCI
conversion using OPLS and showed that combinative power of them were better than
MCI and CSF separately (Westman, et al., 2012c).
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5.2
5.2.1
The

Methodology
Dataset
data

used

in

this

article

were

downloaded

from

ADNI

website

(https://ida.loni.usc.edu/login.jsp). All recruited participants were between 55-90
(inclusive) years of age, had a reliable study partner, able to provide an independent
evaluation of functioning, and speak either English or Spanish. They were willing and
able to undergo all test procedures including neuroimaging and lumbar puncture and
agreed to longitudinal follow up. Specific psychoactive medications were excluded.

5.2.2

Inclusion and diagnostic criteria

As this study aimed to find the discriminative power of features extracted from MRI and
PET imaging modalities, only subjects with valid FDG and AV-45-PET scans and MRI
measures passing visual quality control (QC) evaluation at baseline were included. This
yielded a total of 524 subjects qualified for this study (CN = 137, EMCI = 214, LMCI =
103

and

AD

=

70)

as

of

February

2014

on

ADNI

website

(https://ida.loni.usc.edu/login.jsp). The demographics and clinical characteristics of all
participants are as shown in Table 19.

Diagnostic criteria for CN, EMCI, LMCI and AD are based on ADNI protocol (online:
http://www.adni-info.org/pdfs/adni_protocol_9_19_08.pdf). CN subjects: MMSE scores
between 24 and 30 (inclusive), a CDR of 0, non-depressed, non-MCI, and non-demented;
EMCI subjects: MMSE scores between 24 and 30 (inclusive), a subjective memory
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concern reported by subject, informant, or clinician, objective memory loss measured by
education adjusted scores on delayed recall of one paragraph from Wechsler Memory
Scale Logical Memory II (WMSLM II) (≥16 years: 9-11; 8-15 years: 5-9; 0-7 years: 36), a CDR of 0.5, absence of significant levels of impairment in other cognitive domains,
essentially preserved activities of daily living, and an absence of dementia; LMCI
subjects: Same as EMCI with a difference only in objective memory loss measured by
education adjusted scores on delayed recall of one paragraph from WMSLM II(≥16
years: ≤8; 8-15 years: ≤4; 0-7 years: ≤2); Mild AD Subjects: MMSE scores between
20 and 26 (inclusive), a CDR of 0.5 or 1.0, and meets NINCDS/ADRDA criteria for
probable AD.

5.2.3

MRI and PET

Both MRI and PET scans were at baseline. MRI scans were acquired from a variety of 3T
scanners

with

protocols

individualized

for

each

scanner,

as

defined

in

(http://adni.loni.usc.edu/methods/documents/mri-protocols/). Briefly, all PET images
were acquired 30 to 60 minutes post-injection, co-registered, averaged, reoriented into a
standard 160×160×96 voxel image grid, and smoothed to a uniform isotropic resolution
of 8 mm full width of maximum. A detailed description of PET protocols and acquisition
procedures can be found in: http://adni.loni.usc.edu/methods/pet-analysis/pre-processing..
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1.09 ± 0.19

AV45

1.17 ± 0.22

6.4 ± 0.6

12.1 ± 5.7

7.9 ± 3.4

28.5 ±1.4

15.5 ± 2.6

70.6 ± 6.8

29/41

70

1.29 ± 0.23

6.2 ± 0.8

18.2 ± 7.2

11.2 ± 4.9

27.5 ± 1.8

16.7 ± 2.7

71.2 ± 7.4

33/37

70

1.41 ± 0.18

5.3 ± 0.7

31.8 ± 8.7

21.2 ± 7.5

22.8 ± 2.1

15.9 ± 2.6

75.0 ± 7.9

31/39

70

1.11 ± 0.17

6.6 ± 0.6

9.4 ± 5.0

6.2 ± 3.5

29.0 ± 1.3

16.3 ± 2.6

73.6 ± 5.4

38/29

67

1.16 ± 0.20

6.5 ± 0.6

12.5 ± 5.1

7.8 ± 3.5

28.4 ± 1.6

16.3 ± 2.6

69.6 ± 7.0

69/75

144

EMCI

1.30 ± 0.24

6.5 ± 0.6

18.6 ± 7.3

11.8 ± 5.1

27.9 ± 1.9

16.1 ± 2.8

70.9 ± 8.5

16/17

33

LMCI

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

0.192

< 0.001

0.865†

-

p-value*

Data are represented as mean ± standard deviation where applicable. ADAS-11 = 11-item Alzheimer’s Disease Assessment Scalecognitive subscale, ADAS-13 = 13-item Alzheimer’s Disease Assessment Scale-cognitive subscale, FDG = PET with [18F]fluorodeoxyglucose (FDG), AV45 = PET with 18F-AV-45 (florbetapir). *Unless otherwise noted, Student’s t-tests were
performed for the listed factors between CN and AD in the training set and p-values were shown with those large than 0.05
deemed significant as bolded. †P value of Fisher’s exact test that was performed between CN and AD in the training set.

6.6 ± 0.5

FDG

29.2 ± 1.0

MMSE

8.9 ± 4.0

16.5 ± 2.4

Years of education

ADAS-13

73.6 ± 6.6

Age

5.5 ± 2.6

33/37

Gender (female/male)

ADAS-11

70

Number

AD

CN

LMCI

CN

EMCI

Testing set

Training Set

Table 19: Demographics and characteristics of participants

5.2.4

Image analysis

Cortical reconstruction and volumetric segmentation of MRI images were done by
applying FreeSurfer 5.1 (available online: http://surfer.nmr.mgh.harvard.edu/) to T1
weighted MRI image (MPR or IRSPGR) in NiFTI format which has been pre-processed
(gradient warping, scaling, B1 correction and N3 inhomogeneity correction) by Mayo
Clinic. The detailed technical procedures were described in prior publications (Dale, et al.,
1999a; Fischl and Dale, 2000; Fischl, et al., 2002b; Fischl, et al., 2004b). In this study,
FreeSurfer generated 271 applicable MRI features which passed QC evaluation by Mayo
Clinic as shown in Table 20, Table 21, Table 22, Table 23 and Table 24, with Table 24
showing all the 15 features extracted from PET scans including 8 features from AV-45PET and 7 from FDG-PET. These tables also include the p values to indicate those
features that are significant in separating the AD, EMCI and LMCI groups from CN
subjects.

Data presented in Table 20 to Table 24 are p values of Student’s t-test for left and right
hemispheres separated by ‘|’ where applicable. Regional or composite features shown
significant between any comparing groups were bolded and with “ns” indicating as not
significant,
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Table 20: Statistical significance of cortical volumes by lobes

Frontal Lobe
Superior Frontal
Rostral Middle Frontal
Caudal Middle Frontal
Pars Opercularis
Pars Triangularis
Pars Orbitalis
Lateral Orbitofrontal
Medial Orbitofrontal
Precentral
Paracentral
Frontal Pole
Parietal Lobe
Superior Parietal
Inferior Parietal
Supramarginal
Postcentral
Precuneus
Temporal Lobe
Superior Temporal
Middle Temporal
Inferior Temporal
Bankssts†
Fusiform
Transverse Temporal
Entorhinal
Temporal Pole
Parahippocampal
Occipital Lobe
Lateral Occipital
Lingual
Cuneus
Pericalcarine
Miscellaneous
Insula
Caudal Anterior Cingulate
Isthmus Cingulate
Posterior Cingulate
Rostral Anterior Cingulate
Hemisphere WM*
ICV*

EMCI

Cortical volumes
LMCI

ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns

<0.001|0.002
ns | ns
ns | ns
ns | ns
ns | ns
ns|<0.001
<0.001|0.005
ns | ns
ns | ns
ns | ns
ns | ns

<0.001|<0.001
ns|<0.001
0.005|0.002
ns | ns
0.016| ns
0.002|<0.001
<0.001|<0.001
ns|<0.003
ns | ns
0.002|ns
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns
ns | ns

ns | ns
0.003|0.002
0.017| ns
ns | ns
ns | ns

<0.001|<0.001
<0.001|<0.001
<0.001|<0.001
0.019| ns
<0.001|<0.001

ns | ns
ns | ns
0.005|0.034
ns | ns
ns | ns
ns | ns
ns | ns
0.009| ns
ns | ns

<0.001|ns
<0.001|<0.001
<0.001|<0.001
0.014|0.012
<0.001|<0.001
ns | ns
<0.001|<0.001
0.002|<0.001
0.004|0.014

<0.001<0.001
<0.001|<0.001
<0.001|<0.001
<0.001|<0.001
<0.001|<0.001
ns | ns
<0.001|<0.001
<0.001|<0.001
<0.001|<0.001

ns | ns
ns | ns
ns| 0.010
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns

0.005|0.002
0.020| ns
ns | ns
ns | ns

0.017| ns
ns | ns
0.047|0.042
ns | ns
ns | ns
ns | ns

0.002|0.004
ns | ns
ns | ns
ns|0.045
ns|<0.001
ns | ns

<0.001|<0.001
ns | ns
0.005| ns
<0.001|<0.001
<0.001| ns
ns | ns
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AD

Table 21: Statistical significance of cortical thickness by lobes
Cortical thickness
LMCI

EMCI
Frontal Lobe
Superior Frontal
Rostral Middle Frontal
Caudal Middle Frontal
Pars Opercularis
Pars Triangularis
Pars Orbitalis
Lateral Orbitofrontal
Medial Orbitofrontal
Precentral
Paracentral
Frontal Pole
Parietal Lobe
Superior Parietal
Inferior Parietal
Supramarginal
Postcentral
Precuneus
Temporal Lobe
Superior Temporal
Middle Temporal
Inferior Temporal
Bankssts†
Fusiform
Transverse Temporal
Entorhinal
Temporal Pole
Parahippocampal
Occipital Lobe
Lateral Occipital
Lingual
Cuneus
Pericalcarine
Miscellaneous
Insula
Caudal Anterior Cingulate
Isthmus Cingulate
Posterior Cingulate
Rostral Anterior Cingulate
Hemisphere WM*
ICV*

AD

ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
0.024| ns
ns | ns
ns | ns
ns | ns

0.004|0.007
ns | ns
0.012| ns
0.003| ns
ns | ns
ns | ns
0.049| ns
0.004| ns
ns | ns
ns | ns
ns | ns

<0.001|<0.001
<0.001| ns
<0.001|<0.001
0.002|0.017
0.013| ns
ns |<0.001
<0.001|<0.001
0.015|0.012
0.018|0.045
0.003|0.028
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns
ns | ns

ns | ns
<0.001|0.028
0.0059| ns
ns | ns
0.002|<0.001

<0.001|<0.001
<0.001|<0.001
<0.001|0.002
0.023|0.009
<0.001|<0.001

ns | ns
ns | ns
0.002| ns
ns | ns
0.018|0.036
ns | ns
0.014|0.031
0.022|0.022
ns | ns

<0.001|0.002
<0.001|0.002
<0.001|<0.001
0.015| ns
<0.001|0.002
ns | ns
<0.001|<0.001
<0.001|<0.001
ns | ns

<0.001|<0.001
<0.001|<0.001
<0.001|<0.001
<0.001|<0.001
<0.001|<0.001
ns | ns
<0.001|<0.001
<0.001|<0.001
<0.001|<0.001

ns | ns
ns | ns
ns | ns
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns

0.006|0.005
0.013|0.044
0.036| ns
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
-

0.003|0.012
ns | ns
0.011|0.009
ns | ns
ns | ns
-

<0.001|<0.001
ns | ns
<0.001|<0.001
<0.001|0.008
0.005| ns
-
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Table 22: Statistical significance of surface area by lobes
Surface area
LMCI

EMCI

AD

Frontal Lobe
Superior Frontal
Rostral Middle Frontal
Caudal Middle Frontal
Pars Opercularis
Pars Triangularis
Pars Orbitalis
Lateral Orbitofrontal
Medial Orbitofrontal
Precentral
Paracentral
Frontal Pole
Parietal Lobe
Superior Parietal
Inferior Parietal
Supramarginal
Postcentral
Precuneus
Parietal Lobe
Superior Temporal
Middle Temporal
Inferior Temporal
Bankssts†
Fusiform
Transverse Temporal
Entorhinal
Temporal Pole
Parahippocampal
Occipital Lobe
Lateral Occipital
Lingual
Cuneus
Pericalcarine
Miscellaneous
Insula
Caudal Anterior Cingulate
Isthmus Cingulate
Posterior Cingulate
Rostral Anterior Cingulate
Hemisphere WM*
ICV*

ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
0.015| ns
ns | ns
ns | ns
ns | ns

0.008| ns
ns |0.009
ns | ns
ns | ns
ns | ns
0.037|0.027
0.008| ns
ns | ns
ns | ns
ns | ns
ns | ns

0.015| ns
0.001|<0.001
ns | ns
ns | ns
ns | ns
0.006|0.021
0.003| ns
ns | ns
ns | ns
ns | ns
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns
0.021| ns

ns | ns
ns |0.026
ns | ns
ns | ns
ns | ns

ns | ns
<0.001|<0.001
0.016|0.034
ns | ns
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns
ns | ns

ns | ns
0.011|<0.001
<0.001|0.007
0.047|0.040
0.008| ns
ns | ns
ns |0.044
ns|0.013
0.018|0.023

0.022| ns
<0.001|<0.001
<0.001|<0.001
0.002|<0.001
0.004|<0.001
ns|0.044
ns | ns
ns | ns
<0.001|0.022

ns | ns
ns | ns
ns|0.021
ns | ns

ns | ns
ns | ns
ns | ns
ns | ns

ns | ns
0.039| ns
ns | ns
ns | ns

ns | ns
ns | ns
0.022| ns
ns | ns
ns | ns
ns | ns
-

ns | ns
ns | ns
ns |0.036
ns |0.048
ns | ns
0.037|0.043
-

0.018| ns
ns | ns
ns | ns
ns | ns
ns | ns
0.001|<0.001
-
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Table 23: Statistical significance of subcortical volumes by lobes
Subcortical volumes

EMCI

LMCI

AD

Brainstem

ns

ns

ns

CC Anterior

ns

ns

0.012

CC Central

ns

ns

0.010

CC Middle Anterior

ns

ns

0.034

CC Middle Posterior

ns

ns

ns

CC Posterior

ns

ns

0.022

Cortical GM

ns

<0.001

<0.001

Cortical WM

ns

0.030

0.008

CSF

ns

0.012

<0.001

Fourth Ventricle

ns

ns

ns

Non WM Hypo-Intensities

ns

ns

ns

Optic Chiasm

ns

ns

ns

Subcortical GM

ns

0.021

<0.001

Supra Tentorial

ns

0.002

<0.001

Third Ventricle

0.046

0.003

<0.001

ns

<0.001

<0.001

0.005

0.008

<0.001

0.037| ns

0.004|<0.001

< 0.001|<0.001

0.002|0.007

<0.001|<0.001

< 0.001|< 0.001

Caudate

ns | ns

ns | ns

ns|0.049

Cerebellum Cortex

ns | ns

ns | ns

ns | ns

Cerebellum WM

ns | ns

ns | ns

<0.001|ns

Choroid Plexus

ns | ns

ns | ns

0.018|0.008

Cortical GM

ns | ns

<0.001|<0.001

<0.001|<0.001

Cortical WM

ns | ns

0.027|0.035

0.006|0.013

Hippocampus

0.005|0.002

<0.001|<0.001

< 0.001|<0.001

Inferior Lateral Ventricle

0.002|0.021

<0.001|<0.001

<0.001|<0.001

Lateral Ventricle

ns | ns

0.004|0.013

<0.001|<0.001

Pallidum

ns | ns

0.027| ns

ns | ns

Putamen

ns | ns

ns | ns

<0.001|<0.001

Thalamus

0.034| ns

0.038| ns

<0.001|<0.011

VentralDC

ns | ns

ns | ns

ns | ns

Vessel

ns | ns

ns | ns

ns | ns

Total GM
WM Hypo-Intensities
Accumbens Area
Amygdala
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Table 24: Statistical significance of hippocampus subfields and PET features
Hippocampus Subfields

EMCI

LMCI

AD

CA 1

ns | ns

0.004|<0.001

<0.001|<0.001

CA 2-3

0.010|0.006

<0.001|<0.001

<0.001|<0.001

CA 4 (Dentate Gyrus)

0.023|0.006

<0.001|<0.001

<0.001|<0.001

Fimbria

ns | ns

<0.001|0.016

<0.001|<0.001

Hippocampal Fissure

ns | ns

ns | ns

ns | ns

0.029| ns

<0.001|<0.001

<0.001|<0.001

Subiculum

ns | ns

<0.001|<0.001

<0.001|<0.001

Tail

ns | ns

<0.001|<0.001

<0.001|<0.001

Cerebellum GM

ns

ns

ns

Whole cerebellum

ns

0.017

0.002

Brainstem

ns

0.002

<0.001

Frontal

ns

<0.001

<0.001

Cingulate

ns

0.002

<0.001

Parietal

ns

<0.001

<0.001

Temporal

ns

<0.001

<0.001

0.017

<0.001

<0.001

ns

0.003

< 0.001

Temporal

0.011| ns

0.002| ns

<0.001|<0.001

Angular

0.016| ns

<0.001|0.009

<0.001|<0.001

FDG_sum

ns

<0.001

<0.001

Weighted average

ns

<0.001

<0.001

Presubiculum

AV-45 PET

Summary of SUVR
FDG PET
Cingulum Post (Bilateral)

Processing of AV-45 PET scans was detailed in a prior article (Landau and Jagust,
2011a). Briefly, native-space MRI scans of subjects were used to define 4 cortical grey
matter regions of interest (ROIs), i.e., frontal, anterior/posterior cingulate, lateral parietal
and lateral temporal and 3 reference regions, i.e., cerebellar grey matter, whole
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cerebellum and brainstem. Each florbetapir scan was co-registered to corresponding MRI
and then the mean florbetapir uptake within the 7 cortical and reference regions was
calculated as 7 regional AV-45 PET feature. Also a florbetapir composite feature (i.e.
summary of standardized uptake value ratio (SUVR)) for each subject was created by
non-weighted averaging across the 4 cortical regions and dividing this average by one of
the reference regions (brainstem was used in this study).

Processing of FDG PET scans was detailed in another article(Landau and Jagust, 2011b) .
Basically 5 MetaROIs (i.e. left and right Angular Gyrus, bilateral Posterior Cingular, left
and right Inferior Temporal Gyrus) were identified by Landau et al. through well-defined
procedures based on coordinates cited frequently in other FDG studies comparing AD,
MCI, and CN(Landau, et al., 2011). In this article, 7 FDG features were considered,
including FDG uptakes of the 5 MetaROIS and two other composite features, namely the
sum and weighted average of FDG uptakes of the aforementioned 5 MetaROIs to
represent FDG uptake level of the whole brain.

5.2.5

Preprocessing of data

All MRI measures were adjusted for age and ICV as per Equation (5.1) if the p value of
the linear regression between the measure and the testing factor was smaller than 0.05.
The aim was to remove potential biases from further analysis.

V = V

−G

∙ (V

−V
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)−G

∙ (A − A )

(5.1)

where V is the adjusted measure, V

is the unadjusted measure, V

subject ICV and age (years), respectively; V
all the controls. The gradients G

and G

and A are the

and A are the corresponding means for
were derived by a region-specific linear

regression against subject ICV and age of all the participants. As per Chiang et al.(Chiang,
et al., 2011), the above regression also has the advantage that the the regression order of
age and ICV does not affect the regression result. Then all data was processed by mean
centering and unit variance scaling.

5.2.6

Multivariate data analysis

The aforementioned 286 features were used as inputs to OPLS (Bylesjo, et al., 2006;
Trygg and Wold, 2002), a supervised multivariate data analysis method comes with the
software package SIMCA-P (version 11.5, Umetrics AB, Umea, Sweden). OPLS
removes variation from descriptor variables that is not related to group separation and the
information related to class separation is found in the predictive component (Trygg and
Wold, 2002).

The predictive power of OPLS model for separating two groups is found in Q (Y) and is
defined as follows:

Q (Y) = 1 − PRESS⁄SSY

(5.2)

.

where PRESS (predictive residual sum of squares) = ∑(y

−y

squared differences between observed and predicted Y-values, and SSY
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) , is the
.

represents

the total variation of the Y variable (diagnosis) after scaling and mean centering
(Eriksson, et al., 2006). Q (Y) denotes the predictive power resulting from a 7-fold cross
validation (by default). This procedure is repeated until every observation has been kept
out once and only once. In this type of model, a Q (Y) value larger than 0.5 is regarded
as good (Eriksson, et al., 2006).

Variable influence in the projection (VIP) reflects significance of variables both with
respect to Y (diagnosis) and X (the features included). It summarizes the overall
contribution of each X-variable, summed over all other components and weighted
according to the Y variation accounted by each component (Eriksson, et al., 2006;
Galindo‐Prieto, et al., 2014; Guyon and Elisseeff, 2003). And VIP has been shown to be
critically important in selecting the significant variables (Ray, 2012; Weljie, et al., 2007).
Variables with a VIP score larger than 1 are deemed significant as the average of squared
VIP scores is equal to 1(Eriksson, et al., 1995; Guyon and Elisseeff, 2003; Ray, 2012;
Weljie, et al., 2007).

Multivariate analysis was done for the following two groups of models.

Full models: They included 7 single models and 3 hierarchical models for AD vs. CN,
LMCI vs. CN and EMCI vs. CN. Single models used one of the 5 sets of MRI measures
(i.e. subcortical volumes, cortical volumes, cortical thickness average, surface area and
hippocampus subfields) or features from one of the PET (AV-45 or FDG) scans to
explore discriminative power of different types of measures within the imaging
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modalities. Three hierarchical models included one with all 5 sets of MRI measures,
another one with two PET measures and a third one with all of them combined.

Feature-selected models: The aim of feature selection was to investigate if proper
exclusion of less significant features would reduce inconsistent noisy patterns, and
therefore enhance predictability. To this end, two feature selection methods were applied
to differentiate EMCI, LMCI and AD from CN. The first scheme was commonly used
feature selection technique that only those statistically significant features with a p value
less than 0.05 were selected for each classification type. The other one was implemented
iteratively based on VIP scores. At first, variables with VIP scores larger than 1 were
selected from full models to create feature-selected models with one iteration of feature
selection. Then feature-selected models with 2 iterations of feature selection included
variables with VIP larger than 1 in the previous feature-selected models with one
iteration. The same procedure was repeated to create more feature-selected models until
the model reported a zero predictive power characterized by a Q (Y) value of 0. The
advantage of the VIP-based feature selection technique over the p value-based technique
is that VIP score of the variable varies depending on the other variables included in the
model, making it possible to iteratively exclude less significant variables from the model
and explore predictive power of selected features.

5.2.7

Validation with external test set

Due to stringent inclusion criteria of subjects (i.e. subjects must have eligible MRI, valid
FDG and AV-45 PET scans), among the four comparing groups, AD group has the
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smallest sample size with 70 qualified subjects. In order to maintain high statistical power
and avoid bias due to sample size discrepancy between groups during the training process,
70 subjects were randomly selected from the other three groups (CN, EMCI and LMCI)
to match with the size of AD group, and the remaining subjects were defined as test set as
shown earlier in Table 19.

Best full models and feature-selected models of LMCI vs. CN and EMCI vs. CN were
validated using the combined LMCI-CN and EMCI-CN groups, respectively. To explore
how best AD models recognize EMCI and LMCI subjects from CN, the best models of
LMCI and EMCI were also cross validated with AD and CN subjects in the test set.

5.3
5.3.1

Results
Significance of features in separating groups

To interpret how the features may potentially contribute to separation, Student’s t–test
was performed for each feature between AD (EMCI or LMCI) and CN and the p values
were as shown in Table 20 to Table 24. As expected, more variables showing significant
difference were observed for discriminating AD from CN, and more MRI features of
cortical volumes and cortical thickness were found significant than for surface area.

In terms of lobes, most significant regions were seen in temporal lobe with the least seen
in occipital lobe. Almost all hippocampal subfields were shown significant for LMCI and
AD except for hippocampal fissure. In particular, considering hemispheric symmetry,
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most hemispheric measures showed similarity between hemispheres and asymmetric
measures were mostly significant for the left hemisphere. Interestingly, SUVR across the
whole brain, (defined as “summary of SUVR” in Table 24) was the only AV-45 PET
measure that was shown to be significant for separating any stages of AD from CN.
Besides, volumes of inferior temporal, amygdala, hippocampus, inferior lateral ventricle,
and cortical thickness of fusiform and temporal were also shown significant between any
of the compared groups.

5.3.2

Predictive power of OPLS models

Predictive power of full models: Predicative power (Q (Y)) for the aforementioned full
models without feature selection is summarized in Table 25, which shows that combining
MRI and PET features had the highest predictive power for models predicting LMCI and
AD groups from the CN group, while using cortical thickness alone yielded a higher
Q (Y) for EMCI than using any measures, even when all features were combined.

Separation efficiency of the best full models during the training process could also be
visualized with scatter plots as illustrated in Figure 16. Perfect separation of AD from CN
using all features is shown in Figure 16A with a high Q (Y) of 0.721. Moreover, Figure
16B and Figure 16C show that the models are efficient in separating LMCI and EMCI
from CN as well.

Predictive power of feature-selected models: The two feature selection schemes using
VIP scores and p values were applied to all features for EMCI, LMCI and AD against CN.
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In addition, they were also applied to cortical thickness for EMCI prediction as cortical
thickness was shown previously as the best full model in predicting EMCI. Predictive
power of feature-selected models iteratively created with VIP function of SIMCA
software are given in Figure 17 with black curves, of which the first point represents the
predictive power of model with all features and the other points indicate predictive power
of VIP-based feature-selected models with different numbers of iterations. Predictive
power of p value-based feature-selected models was also shown in Figure 17 with
straight or dotted lines. It could be seen that appropriate feature selection boosted
predictive power as the linear segments kept rising up to a point, then began to drop as
less and less features were selected in this iterative process. The results also showed that
feature selection based on VIP scores offered more flexibility in selecting the best models
with a peak predictive power higher than that obtained using statistical feature selection
method.

In terms of numbers of iteration, Figure 17 indicates that for LMCI and AD prediction, 2
to 3 iterations of VIP-based feature selection yielded the maximal predictive power,
while for EMCI prediction, no matter whether using all features or cortical thickness only,
1 iteration of VIP-based feature selection could already achieve the highest predictability.
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Table 25: Summary of predictive power (
Models

MRI

PET

( )) for all full models

EMCI

LMCI

AD

Subcortical volume

N/A

0.188

0.585

Cortical volume

N/A

0.257

0.528

Cortical thickness

0.108

0.154

0.538

Surface area

N/A

0.040

0.202

Hippocampus Subfields

0.029

0.277

0.547

Combined

N/A

0.282

0.645

18F-AV-45

0.076

0.227

0.518

FDG

0.038

0.055

0.512

Combined

0.093

0.229

0.636

0.008

0.294

0.721

MRI+PET

N/A = Models had 0 predictive power (Q (Y)), FDG = PET with [18F]-fluorodeoxyglucose,
AV45 = PET with 18F-AV-45 (florbetapir). The hierarchical models were italicized and highest
Q (Y)for three classification types were bolded.

5.3.3

Model validation with external test set

The best full models of EMCI and LMCI, shown as bolded in Table 25, were validated
with the combined EMCI-CN and LMCI-CN groups, respectively. The same experiments
were also done for best feature-selected models as indicated by the peaks of the curves in
Figure 17. Besides, in order to investigate how models well trained with AD pattern
would recognize and classify EMCI and LMCI subjects from controls in the test set, the
best AD full models and best AD feature-selected models were also cross validated with
EMCI and LMCI subjects against controls using external test set.
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Figure 16: Scatter plots of best full models as indicated in Table 25 for separation
between (A) AD and CN. (B) LMCI and CN (C) EMCI and AD.
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Figure 17: Predictive power ( ( )) of feature-selected models with p representing
feature-selected models based on p values, and VIP denoting feature-selected models
based on VIP scores. All of the feature selection techniques were applied to all features
except for EMCI_CT, which was applied only to cortical thickness as it was shown
previously to have the highest predictive power of EMCI: (top) predictive power of p
value-based and VIP-based feature-selected models of AD and LMCI; (bottom)
Predictive power of p value-based and VIP-based feature-selected models of EMCI using
all features or cortical thickness only.
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Scatter plots of validation for the best full models and best feature-selected models were
shown in Figure 18 and Figure 19, respectively. Classification performance in terms of
accuracy, sensitivity and specificity were summarized in Table 26. Comparing Figure
16C with Figure 18A - Figure 19A, it could be seen that neither best full model nor best
feature-selected model of EMCI separated the testing EMCI from CN as well as it did
during the training process, displaying poor generalization. However, this was not the
case for best LMCI models. Figure 18C - Figure 19C and Figure 16B illustrate good
generalization of LMCI models as LMCI subjects in the test set were classified nearly as
accurately as it did during the training process. Figure 18B - Figure 19B and Figure 18D Figure 19D show that AD models are very efficient in identifying controls, with Table 26
showing high specificity of more than 95%, which are, as expected, higher than the best
EMCI or LMCI models, with LMCI specificity value being higher.
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Figure 18: Scatter plots of best full models validated with external test set. (A) Testing best EMCI model with external
EMCI and CN subjects. (B) Testing best AD model with external EMCI and CN subjects. (C) Testing best LMCI
model with external LMCI and CN subjects. (D) Testing best AD model with external LMCI and CN subjects.
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Figure 19: Scatter plots of best feature-selected models validated with external test set. (A) Testing best featureselected EMCI model with external EMCI and CN subjects. (B) Testing best feature-selected AD model with external
EMCI and CN subjects. (C) Testing best feature-selected LMCI model with external LMCI and CN subjects. (D)
Testing best feature-selected AD model with external LMCI data and CN subjects.

Table 26: Classification performance (accuracy, sensitivity and specificity) for validation
of best EMCI and LMCI models using external test set
EMCI vs. CN

LMCI vs. CN

Accuracy

Sensitivity

Specificity

Accuracy

Sensitivity

Specificity

Best full model of EMCI

48.8%

48.6%

49.3%

-

-

-

Best feature-selected
model of EMCI

49.3%

50.0%

47.8%

-

-

Best full model of LMCI

-

-

-

74.0%

69.7%

76.1%

Best feature-selected
model of LMCI

-

-

-

83.0%

75.8%

86.6%

Best full AD-model

42.7%

18.1%

95.6%

80.0%

48.5%

95.6%

Best feature-selected
model of AD

41.7%

16.0%

97.0%

82.0%

51.5%

97.0%

5.4
5.4.1

Discussion
Significance of MRI and PET features

This study considered MRI measures including hemispheric measures, various sorts of
cortical and subcortical segmentations and parcellation (regional volumes, cortical
thickness and surface area etc.), hippocampal subfields and select regional PET features
(AV-45 PET and FDG PET), making direct comparison of variables in terms of their
importance within and across imaging modalities.

The results in Table 20 to Table 24 confirmed with previous study that atrophy in
temporal lobe was more pronounced than in other lobes and medial temporal atrophy was
highly symmetric, which differ from other dementia, such as semantic dementia with
symmetric atrophy (Chan, et al., 2001; Kohler, et al., 1998). In this study, the following
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hemispheric regional measures were found to be significant for predicting all stages of
the disease: cortical volumes of inferior temporal, cortical thickness of fusiform, temporal
pole, subcortical volumes of hippocampus, inferior lateral ventricle and amygdala,
hippocampal subfields of cornu ammonis 1 (CA 1) and CA 2-3, and PET feature of
SUVR across the brain. This was consistent with our previous study that combining the
first two of the aforementioned 3 subcortical volumes with the neuropsychological test
score yielded an accuracy of 92.4% in predicting AD from CN(Zhou, et al., 2014d).
Besides, discrepancy of regional significance among hippocampal subfields as
demonstrated in Table 24 may have improved differential diagnosis of AD according to a
study by Mueller and Weiner , who reported that subfield volumetry of hippocampus
provides regional selective information for distinguishing different pathologies affecting
the hippocampus (Mueller and Weiner, 2009). It is therefore helpful to include
hippocampal subfields in multivariate study of AD.

Landau et al. found that beta-amyloid deposition has an early and subclinical impact on
cognition preceding metabolic changes and that hypometabolism becomes more
pronounced and more closely related to ongoing cognitive decline as disease progresses
(Landau, et al., 2012). This is consistent with the results in Table 24 that summary of
SUVR across the whole brain as defined earlier in the method section, was the only PET
(AV-45 or FDG) feature showing to be significant when comparing any stages of AD
with CN, and it is the only AV-45 PET feature that is significant in predicting EMCI.
This may imply that at a very early stage of MCI, beta-amyloid deposition could be more
pronounced brain-widely instead of regionally and at such a stage hypometabolism was
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not prominent enough across the brain though showing certain impacts regionally. Wu et
al. also reported similar results in that significant amyloid accumulation is presented in
EMCI while brain metabolism remains normal (Wu, et al., 2012).

5.4.2

Model efficiency with OPLS

This study aimed to investigate the predictive power of MRI and select regional PET
features in discriminating AD, LMCI, and EMCI from controls using OPLS as a
multivariate analysis tool based on a prior OPLS study(Westman, et al., 2011b) . Full
models using all or one category of the features were created for EMCI, LMCI and AD
against CN. Moreover, two feature selection techniques were implemented and featureselected models were created. Cross-validated predictive power Q (Y) was used to
evaluate these models, which were also validated with external test set.

Efficiency of full models with OPLS: To the best of our knowledge about the literature,
this study was the first to analyze EMCI and LMCI separately using OPLS as a
multivariate tool, though study analyzing AD and MCI based on MRI measures using
OPLS has been done. Using the European AddNeuroMed project data, Westman et al.
utilized automated regional volumes and manual outlining of hippocampus as inputs to
OPLS and found a Q (Y) of 0.64 when discriminating AD from CN(Westman, et al.,
2011b), which was consistent with the Q (Y) of 0.645 achieved using only MRI in this
study, the difference could be due to differences in MRI features used and population
differences. In addition, we also showed that PET scans have comparable discriminative
power (Q (Y) = 0.636) with MRI. Westman et al. also built a MCI model with the same
101

features and obtained a Q (Y) of 0.22. Compared with LMCI model using all MRI
features in this study, the predictive power of our model (Q (Y) = 0.282) was higher
which we suspect to be mostly due to the difference between diagnostic criteria of MCI
in AddNeuroMed dataset and LMCI in ADNI dataset, and could also be that MRI
features included in this study contributed more complementary information to the
model.

Interestingly, a model with cortical thickness measures was found to have the most
discriminative power than any other MRI and PET features, even higher than combining
all of them. The same case was not seen for LCMI and AD models, which showed that
volumetric measures had more power. This could be due to the higher reliability of
cortical thickness than of cortical volumes and other MRI measures at the very early
stage of AD (Querbes, et al., 2009). This result is consistent with other studies that
recommend using cortical thickness for MCI prediction (Querbes, et al., 2009; Wang, et
al., 2009). This could also suggest that cortical thinning is the very first anatomical
change that occurs before any other volumetric change or effective response to PET scan,
and as disease progresses volumetric change will eventually dominate.

Since the discriminative power of the best EMCI model is still weak, it can be argued that
this could be due to partitioning errors embedded in the cross validation process that the
data distribution may slightly favor cortical thickness features than others as reflected in
the Q (Y)measure. However, Q (Y) of 0.108 is higher than the threshold (0.05) for
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significance of an OPLS model(Westman, et al., 2011b), therefore the model is still
considered significant and the results are still considered reliable.

Efficiency of feature-selected models with OPLS: Feature selection was also investigated
since it has been reported that feature selection improves classification performance if the
right prior knowledge is used (Chu, et al., 2012). In this study, prior knowledge of VIP
scores in PLS projection was used to iteratively exclude less significant features based on
VIP scores to investigate the predictability of feature-selected models in comparison to
full models which include all features. Feature selection based on p values was also of
interest as it’s a commonly used feature selection technique (Chaves, et al., 2009b; Chu,
et al., 2012).

The results as shown in Figure 17 not only confirmed the results of a previous study
(Chu, et al., 2012) in the use of feature selection based on prior knowledge, it also
showed that recursive feature selection based on VIP scores was effective in enhancing
classification performance better than just using Student’s t test as the only selection
criteria. The reason that models with select features did a better job than models using all
features could be that some of the less significant features contribute little or even
negatively to the separation given their inconsistent variations. It could also mean that
large numbers of input variables may actually overfit the data (Chu, et al., 2012; Guyon
and Elisseeff, 2003).
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5.4.3

Model validation with external test set

In order to avoid potential bias due to sample size differences, the 4 compared groups in
the training process were assigned the same sample size. As the AD group has the least
amount of samples, testing group was not assigned any AD subjects in order to maximize
statistical power by ensuring that sample size is as large as possible for the 4 groups in
the training process. Thus the study should not be criticized for that, as such data
distribution is to fully maximize validity of the results. In addition, the main focus of this
study was to analyze the prodromal stages (EMCI and LMCI) of AD separately. To a
certain extent, the results of this study could also partially imply robustness of AD
models from the following aspects: firstly best full AD model demonstrated perfect
separation of AD and CN with no errors in the training process and Table 26 showed that
best AD models have indeed high specificities of more than 95% during validation using
external test set.

Even though not reflected by the results of EMCI model validation in Table 26, the
EMCI model displayed some generalization as shown in Figure 18A and Figure 19A that
those residing far from the separation boundary on the EMCI side were mostly EMCI
subjects, indicating that these EMCI subjects in the test set share similar pattern as EMCI
subjects in the training set. This could also be an indicator of structural change of brain
(cortical thickness in particular) already showing up at this stage. Overall, due to more
consistency of LMCI patterns, LMCI models were more robust and had better
generalization to external test set than EMCI models.

104

Combining AV-45 and FDG PET scans received a predictive power (Q (Y) = 0.093)
close to that of the cortical thickness, indicating that amyloid deposition and
hypometabolism have emerged at the EMCI stage. As a stage close to AD dementia,
LMCI has its own pattern of atrophy that differentiates it from AD, which could be seen
from Table 26 that best feature-selected model of LMCI predicted external LMCI
subjects better than the best AD models. Table 26 also shows that best AD models are not
as efficient as the best EMCI models in identifying EMCI subjects neither. The cause of
the outcome is mainly due to the fact that significance of ROIs changes as disease
progresses.
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CHAPTER 6

6. CONCLUSION AND FUTURE WORK

6.1
6.1.1

Conclusions from Analyzing Methods
Combining MRI with Neuropsychological Test (MMSE)

The use of different biomarkers for clinical diagnosis of AD and MCI is of great
importance. This study has shown that volumetric MRI measures can better predict AD
(aMCI or naMCI) when combined with MMSE score. The MMSE score is found to be
the most statistically significant variable and one that improves classification accuracy at
any stage of the AD spectrum by over 10%. Particularly MRI measures of right
hippocampus and left inferior lateral ventricle when combined with MMSE score yield a
classification accuracy of 92.4% (sensitivity: 84.0%; specificity: 96.1%) for delineating
AD patients from CN, which is very competitive in comparison to results reported in
other recent studies. The approach considered for selecting and then ranking MMSE and
other MRI variables could be useful at augmenting other classification methods reported
in the literature and could have broader impact in reevaluating the different variables as
predictive measures of AD. In addition, the results show that AD atrophy is widely
spread and evenly seen on both sides, whereas aMCI and naMCI subjects are left side and
right side dominant, respectively, which indicates that at different stages of AD, there
may be hemisphere-dependent atrophy dominance. Also hippocampus atrophy is found in
this study to be one of the key factors causing memory problems among subjects with
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aMCI as compared to naMCI, which builds a linkage between the distinctive symptoms
of the two types of MCI and the brain atrophy, and strongly suggests the use of
hippocampus atrophy as the means to separate aMCI from naMCI.

6.1.2

Investigating Normalization Effect

This dissertation also studied the effect of normalization on the proposed statistical
feature selection approach using ROIs segmented by Freesurfer and a neuropsychological
test in terms of classification performance. The results show that subcortical volume
should not be normalized and surface area does not bear much discriminative information
as compared to subcortical volumes or cortical thickens. Also, subcortical volumes and
cortical thickness based brain maps of significant regions show symmetry between the
two hemispheres which is not seen in the brain maps generated using surface area.
Moreover, the feature selection method implemented on cortical thickness measures
show that normalization to either ICV or mean thickness exhibits an enhancement on the
classification performance, and the most pronounced changes in the cortical thickness
related to AD is seen in the temporal lobe of the brain, which is shown to be related to
symptoms in AD patients regarding organization, language, understanding, etc. A
comparison of results using the optimal model which combines MMSE with subcortical
volumes shows that the proposed study achieved a competitive accuracy of 92.3% using
fewer biomarkers, which makes it cost-effective and convenient.
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6.1.3

Combining MRI with PET

Based on prior study by Westman (Westman, et al., 2011b), this study utilized 271 MRI
features and 15 pre-identified PET (AV-45 and FDG) features as inputs to a multivariate
analysis tool (OPLS) to discriminate EMCI, LMCI and AD from controls based on ADNI
database. The results showed that MRI and PET had similar predictive power of AD and
cortical thickness is a significant measure in identifying EMCI subjects. Feature selection
techniques were implemented to explore models with optimal discriminative power. The
results demonstrated that OPLS is a powerful tool identifying AD and LMCI with great
generalization. Due to insufficiency of consistent pattern between EMCI subjects and
controls, EMCI prediction appeared to suffer from poor generalization. Recursive feature
selection based on VIP enhanced prediction when features were properly selected. Two
to three iterations of VIP-based feature selection were suggested for prediction of AD and
LMCI, and a single iteration was sufficient for prediction of EMCI to achieve optimal
predictability. In addition, models well trained with AD pattern were neither optimized
for EMCI nor for LMCI predictions.

Such study of identifying EMCI and LMCI as independent stages has rarely been done in
the literature as far as we know. As a result, heterogeneity between them has not yet fully
been explored. Multivariate analysis of EMCI and LMCI as was done in this study could
serve as an early step in seeking a solution to this problem, just as pursuing research for
better biomarkers must go on. Since baseline image scans fail to properly predict subjects
at EMCI stage using OPLS, future work to augment early findings of this study needs to
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explore the progressive change of biomarkers (atrophy, amyloid deposition and
hypometabolism level, among others) based on longitudinal scans using OPLS.

Future investigation on this research should be extended to utilize more valid biomarkers
for AD, including PET, CSF, APOE and EEG.. Even though there are not enough
subjects with all these biomarkers available, it would be essential to explore their
complementary discriminative information to achieve better results and find connections
between the different biomarkers. Another direction for future work would be to
exhaustively explore machine learning algorithms for prediction, including feature
selection methods (e.g. subset selection and using regularization) and classification
methods (e.g. random forests and artificial neuron networks).

6.1.4

EMI Approach

There already existing a number of techniques that have been applied to MRI scans for
AD prediction. However, they are mostly based on the techniques such to investigate the
variance in the testing data explained by the variance found through training data as PCA
and PLS etc. The prediction is then obtained using classifiers such as SVM. In this study,
a novel EMI-based approach is proposed, which makes prediction based on a calculated
value without data projection and such a value is directly related to the level of atrophy,
which may potentially serve as an indicator of the severity of the disease. The results of
this study demonstrated that the EMI-based method is very efficient and robust to
external data for disease prediction using only MRI, outperforming even other prior
studies that combined multiple biomarkers. The simplicity in implementation and the
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high and consistent prediction performance suggest that the EMI-based method could
potentially serve as cost-effective tool for the diagnosis of AD.

One important research direction for the future specifically for the EMI method is to
develop a weighted averaging method for calculating EMI value. Since the higher ranked
variables may contain more useful information in calculating the EMI and thus should be
assigned a higher weighting factor. This procedure will be helpful in improving the
classification performance but is also very challenging as different weighting methods
may yield highly varying results and it is hard to justify which one performs better.
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